30-day average of 12 articles · scale −100 to +100
Across 12 scored articles from Oct 16 to Nov 14, 2026 (UTC),
the average sentiment of Gilead Sciences news is Somewhat Bullish (+50)
on a scale from −100 to +100.
That is up 9 points from the previous 30 days (+41).
📈 Gilead Q3 EPS beat estimates by 15.6%, extending six quarters of outperformance.
💰 Revenue rose 6.8% YoY to $8.3B driven by strong HIV franchise performance.
Bullish +65
Gilead Sciences (GILD) Q3 2026 Earnings
AI-generated analysis
Key insights
📈 Gilead reported Q3 2026 non-GAAP EPS of $2.55, beating the $2.21 consensus estimate by 15.6% and extending a six-quarter run of exceeding analyst expectations.
💰 Revenue reached $8.3 billion, topping the $7.8 billion estimate by 6.32% and rising 6.8% year over year driven by strong HIV franchise performance.
🔬 HIV sales surged 18% to drive overall growth, with Biktarvy up 10% and prevention revenues nearly doubling due to the rapid commercial ramp of Yeztugo.
📊 Product sales excluding Veklury increased 16% to $8.20 billion, fueled by higher average realized prices and favorable inventory dynamics across key assets.
🚀 Gilead raised full-year 2026 product sales guidance to $31.0–$31.3 billion, a cumulative increase of $1.60 billion since the start of the year.
⚖️ Product gross margin expanded to 81.0% non-GAAP following the expiration of a royalty-related obligation, improving profitability on core products.
📉 GAAP diluted EPS declined to $1.94 from the prior year due to net losses from equity securities and higher tax rates, masking underlying operational strength.
💸 Significant acquired IPR&D charges of $12.4 billion are included in guidance, resulting in a projected GAAP diluted loss of $(4.40)–$(4.05) per share for the full year.
📉 Veklury revenues dropped 69% to approximately $300 million as expected due to lower COVID-19 hospitalizations, though guidance remains unchanged at this level.
⚠️ The Biktarvy Medicare Maximum Fair Price is scheduled to affect revenue starting January 1, 2028, potentially impacting future HIV franchise growth.
📈 Bullish signals
📈Gilead delivered a standout Q3 with non-GAAP EPS of $2.55, beating estimates by 15.6% and extending a six-quarter streak of exceeding analyst expectations.
💰Revenue of $8.3 billion surpassed the $7.8 billion consensus, rising 6.8% year over year driven by an 18% surge in HIV sales.
🔬The twice-yearly lenacapavir PrEP product Yeztugo rapidly ramped to generate $305 million, a near-doubling of prevention revenues compared to the prior year.
📊Product sales excluding Veklury grew 16% to $8.20 billion, fueled by higher average realized prices and strong demand for Biktarvy and Descovy.
🚀Gilead raised full-year 2026 product sales guidance to $31.0–$31.3 billion, reflecting confidence in its core business momentum.
⚖️Product gross margin expanded to 81.0% non-GAAP following the expiration of a royalty-related obligation, enhancing profitability on existing assets.
📉 Risk factors
📉GAAP diluted EPS fell to $1.94 from the prior year due to net losses from equity securities and higher operating expenses.
💸Significant acquired IPR&D charges of $12.4 billion weigh heavily on per-share metrics, resulting in a projected full-year GAAP loss of $(4.40)–$(4.05).
📉Cell therapy revenues declined 18% year over year due to competitive headwinds in the sector.
📉Veklury revenues dropped 69% to approximately $300 million as lower COVID-19 hospitalizations reduced demand for the antiviral treatment.
Article
Gilead Sciences reported third-quarter fiscal 2026 earnings on October 29, 2026, significantly beating analyst expectations with non-GAAP EPS of $2.55 versus a consensus of $2.21 and revenue of $8.3 billion against an estimate of $7.8 billion. This performance extended the company's streak of exceeding EPS estimates to six consecutive quarters, driven primarily by robust growth in its HIV franchise where product sales excluding Veklury surged 16% year-over-year.
The standout quarter was fueled by an 18% increase in HIV sales led by the blockbuster drug Biktarvy and a near-doubling of prevention revenues. The twice-yearly lenacapavir PrEP product, Yeztugo, rapidly ramped up to generate $305 million compared to just $39 million a year earlier. Other segments showed mixed results, with liver disease sales rising 13% due to Livdelzi demand and pricing, while cell therapy revenues declined 18% amid competitive headwinds.
Despite the strong operational performance, GAAP diluted EPS fell to $1.94 from the prior year due to net losses on equity securities and higher operating expenses. Gilead raised its full-year 2026 product sales guidance to a range of $31.0 billion to $31.3 billion, reflecting confidence in its core business despite significant acquired IPR&D charges totaling $12.4 billion that weigh heavily on per-share metrics.
Sector and industry come from company profile data. Sentiment is the AI score of the news articles on this page, averaged per day. Not investment advice.
Citi analyst Geoff Meacham maintained a Buy rating on Gilead Sciences (GILD) with a price target of $165.00, based on the company's latest earnings release for the quarter ending March 31. The report highlights that Gilead reported quarterly revenue of $6.96 billion and net profit of $2.02 billion, compared to last year's revenue of $6.67 billion and net profit of $1.32 billion.
In addition to Citi, Wells Fargo analyst Mohit Bansal also issued a Buy rating on Gilead Sciences in a report from yesterday, while RBC Capital maintained a Hold rating as of June 1. The article notes that Meacham covers the Healthcare sector and has an average return of 8.6% with a 54.62% success rate on recommended stocks.
📈 Analysts maintain Buy ratings with a $165 price target for Gilead.
💰 Q1 revenue hit $6.96B while net profit surged to $2.02B.
🔬 Recent Phase 3 results and EASL data drive positive market attention.
📈 Citi analyst Geoff Meacham maintained a Buy rating on Gilead Sciences (GILD) with a price target of $165.00.
💰 The company reported quarterly revenue of $6.96 billion and net profit of $2.02 billion for the quarter ending March 31.
📊 Revenue increased from $6.67 billion last year, while net profit rose significantly from $1.32 billion in the prior year.
🏦 Wells Fargo analyst Mohit Bansal also issued a Buy rating on Gilead Sciences in a report released yesterday.
⚖️ RBC Capital maintained a Hold rating on Gilead Sciences as of June 1, contrasting with the recent upgrades.
👨💼 Analyst Geoff Meacham covers the Healthcare sector and has an average return of 8.6% on recommended stocks.
🔬 Recent headlines highlight Gilead's Phase 3 study results for Livdelzi and new data presented at the EASL congress.
📰 The article notes that Gilead is trending alongside other companies like Eli Lilly, Merck, and Pfizer in analyst coverage.
Bullish Signals
Citi analyst Geoff Meacham maintains Buy on Gilead (GILD) with $165 target.
Wells Fargo's Mohit Bansal also issued a Buy rating on Gilead.
Gilead reported quarterly revenue of $6.96 billion, up from $6.67 billion.
Net profit reached $2.02 billion, up from $1.32 billion last year.
Risk Factors
RBC holds Gilead (GILD), signaling lack of analyst bullishness.
Bullish Signals
Citi analyst Geoff Meacham maintained a Buy rating on Gilead Sciences (GILD) with a price target of $165.00.
Wells Fargo's Mohit Bansal also issued a Buy rating on Gilead Sciences in a report released yesterday.
Gilead reported quarterly revenue of $6.96 billion, representing growth from last year's revenue of $6.67 billion.
The company achieved a net profit of $2.02 billion for the quarter ending March 31, up significantly from $1.32 billion in the same period last year.
Risk Factors
RBC Capital maintained a Hold rating on Gilead Sciences (NASDAQ: GILD) as of June 1, indicating some analysts are not bullish enough to recommend buying the stock.
Gilead Sciences and Lakefront Biotherapeutics have completed the acquisition of Ouro Medicines to advance T cell engager therapies for autoimmune diseases. The deal involves Gilead acquiring all outstanding equity of Ouro Medicines for $1,675 million plus up to $500 million in contingent milestone payments, with Lakefront and Gilead splitting the upfront payment and milestones equally. This transaction adds gamgertamig (OM336), a clinical-stage BCMAxCD3 T cell engager, to Gilead's inflammation portfolio and serves as the foundation of Lakefront's pipeline. Gamgertamig is designed for rapid and deep plasma cell and B cell depletion via subcutaneous administration, targeting severe antibody-mediated orphan diseases like autoimmune hemolytic anemia (AIHA) and immune thrombocytopenia (ITP). It holds Fast Track and Orphan Drug Designation from the FDA and is expected to enter registrational studies as early as 2027.
Under the agreement, Lakefront will lead Phase 1/2 clinical studies while Gilead leads registrational and later-stage studies. Gilead retains sole worldwide commercialization rights outside Keymed's territories, with Lakefront receiving tiered royalties of 20%-23% on net sales. Additionally, Lakefront has in-licensed a preclinical portfolio of three autoimmune programs from Ouro with an opt-in for Gilead for a 50/50 profit split post clinical proof-of-concept at $75 million per program. The transaction provides relief under the Option, License and Collaboration Agreement between Lakefront and Gilead, enabling Lakefront to deploy at least $500 million of its available cash independently, including up to $150 million for share buybacks. Lakefront expects a year-end 2026 cash balance of approximately €2B, maintaining liquidity for additional strategic transactions.
🏛️ Gilead and Lakefront completed Ouro Medicines acquisition to expand inflammation pipeline.
💰 Deal includes $1,675M upfront payment plus up to $500M in milestones.
🔬 Gamgertamig is a clinical-stage BCMAxCD3 T cell engager for autoimmune diseases.
⚡ FDA Fast Track designation granted with registrational studies expected by 2027.
🏛️ Gilead Sciences and Lakefront Biotherapeutics have officially completed the acquisition of Ouro Medicines to expand their inflammation pipeline.
💰 The deal involves an upfront payment of $1,675 million split equally between Gilead and Lakefront, plus up to $500 million in contingent milestone payments.
🔬 The primary asset acquired is gamgertamig (OM336), a clinical-stage BCMAxCD3 T cell engager designed for autoimmune diseases like AIHA and ITP.
⚡ Gamgertamig has received Fast Track and Orphan Drug Designation from the U.S. FDA and is expected to enter registrational studies as early as 2027.
🤝 Gilead will lead registrational and later-stage studies while Lakefront Biotherapeutics is responsible for ongoing Phase 1/2 clinical development.
🌍 Gilead retains sole worldwide commercialization rights outside of Keymed's territories, which holds rights to develop the program in Greater China.
💸 Lakefront will receive tiered royalties ranging from 20% to 23% on net sales of gamgertamig from Gilead.
📜 The transaction includes an option for Lakefront to in-license three additional preclinical autoimmune programs with a potential $75 million per program profit split.
💼 This acquisition provides Lakefront with relief under its existing Option, License and Collaboration Agreement (OLCA) with Gilead.
💶 Following the deal, Lakefront expects to maintain approximately €2 billion in cash at year-end 2026 for further strategic transactions.
🎯 The partnership aims to shift treatment paradigms from chronic disease management toward durable immune reset for severe antibody-mediated orphan diseases.
📈 Gilead continues its long-term strategy of investing in differentiated science and accelerating therapies for significant unmet needs.
Bullish Signals
Gilead acquires Ouro Medicines for $1.675B plus up to $500M milestones.
Deal adds gamgertamig (OM336) with FDA Fast Track and Orphan Drug Designation.
Gamgertamig enters registrational studies as early as 2027 for autoimmune diseases.
Lakefront receives tiered royalties of 20%-23% on net sales of gamgertamig.
Transaction enables Lakefront to deploy at least $500M cash independently.
Lakefront's year-end 2026 cash balance expected to be approximately €2B.
Gilead invests $32 billion in 2025 to strengthen U.S. footprint and discovery.
Gilead operates in more than 35 countries worldwide for broad global reach.
Risk Factors
$1.675B+ acquisition strains liquidity and impacts other priorities.
Lakefront limited to 20%-23% royalties; Gilead keeps global rights.
Risks include failed integration and benefits not materializing.
Regulatory approval and trial results remain uncertain.
Bullish Signals
Gilead Sciences and Lakefront Biotherapeutics successfully completed the acquisition of Ouro Medicines for $1,675 million plus up to $500 million in contingent milestone payments, significantly expanding Gilead's inflammation pipeline.
The deal adds gamgertamig (OM336), a clinical-stage BCMAxCD3 T cell engager with Fast Track and Orphan Drug Designation from the U.S. FDA, to Gilead's portfolio for treating autoimmune diseases like AIHA and ITP.
Gamgertamig is expected to enter registrational studies as early as 2027, offering a potential first-in-class therapy designed to induce durable disease control in severe antibody-mediated orphan diseases.
Lakefront Biotherapeutics will receive tiered royalties of 20%-23% on net sales of gamgertamig from Gilead, providing a strong revenue stream for the partner company.
The transaction provides relief under the existing Option, License and Collaboration Agreement, enabling Lakefront to deploy at least $500 million of its available cash independently, including up to $150 million for share buybacks.
Following the acquisition, Lakefront's year-end 2026 cash balance is expected to be approximately €2B, leaving a majority of its cash remaining for additional strategic transactions and capital allocation priorities.
Lakefront has also in-licensed a preclinical portfolio of three additional autoimmune-focused programs with an opt-in for Gilead for a 50/50 profit split post clinical proof-of-concept for $75 million per program.
Gilead's long-term strategy to invest in differentiated science is reinforced by this acquisition, supporting its ambition to shift treatment paradigms from chronic disease management toward the potential for durable immune reset.
The collaboration leverages Gilead's existing expertise in immunology and cell therapy, combining with Ouro Medicines' assets to accelerate the development of therapies addressing significant unmet need.
Gilead announced a planned $32 billion investment in 2025 to further strengthen its U.S. footprint to power the next era of discovery, job creation, and public health preparedness while continuing to invest globally.
Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, Calif., ensuring a broad global reach for its scientific innovation.
Lakefront Biotherapeutics combines world-class deal making expertise with capital to identify, acquire, and advance promising opportunities that have the potential to drive value for patients and shareholders.
The company prioritizes oncology and immunology inflammation programs with clear clinical proof-of-concept in emerging areas, applying a modality-agnostic asset selection approach.
Risk Factors
The acquisition of Ouro Medicines for $1,675 million plus up to $500 million in contingent milestone payments represents a significant capital outlay that could strain liquidity or impact other strategic priorities.
Gilead retains sole worldwide commercialization rights outside Keymed's territories, meaning Lakefront will receive only tiered royalties of 20%-23% on net sales, limiting Lakefront's direct revenue upside from the asset.
The transaction relies on gamgertamig entering registrational studies as early as 2027, introducing a long timeline to potential commercialization and delaying any return on this substantial investment.
Forward-looking statements explicitly warn of risks including unsuccessful integration, failure to realize expected benefits from the acquisition, and the possibility that actual results may differ materially from expectations.
The press release includes standard risk disclosures regarding the difficulty of predicting regulatory approval outcomes, potential limitations on use if approved, and the risk of unfavorable clinical trial results.
Gilead Sciences and Lakefront Biotherapeutics have completed the acquisition of Ouro Medicines for a total upfront payment of $1,675 million, with Gilead and Lakefront splitting the cost equally. The deal is designed to expand Gilead's inflammation pipeline by adding gamgertamig (OM336), a clinical-stage BCMAxCD3 T cell engager intended for severe antibody-mediated orphan diseases such as autoimmune hemolytic anemia and immune thrombocytopenia. Gamgertamig has received Fast Track and Orphan Drug Designation from the U.S. FDA and is expected to enter registrational studies as early as 2027, following ongoing Phase 1/2 clinical studies led by Lakefront.
Under the terms of the agreement, Gilead will retain sole worldwide commercialization rights for gamgertamig outside of Keymed's territories in Greater China, while Lakefront will receive tiered royalties ranging from 20% to 23% on net sales. The transaction also includes up to $500 million in contingent milestone payments, which are split between the two parties. Additionally, Lakefront has in-licensed a preclinical portfolio of three other autoimmune programs from Ouro, with an option for Gilead to acquire a 50/50 profit split on these assets post-clinical proof-of-concept for $75 million per program.
This acquisition provides strategic relief under the existing Option, License and Collaboration Agreement between Lakefront and Gilead, allowing Lakefront to deploy at least $500 million of its available cash independently, including up to $150 million for share buybacks. Following the transaction, Lakefront is expected to maintain a year-end 2026 cash balance of approximately €2 billion, preserving capital for additional strategic transactions and operational priorities. The Ouro portfolio will serve as the cornerstone of Lakefront's R&D pipeline, while Gilead continues its long-term strategy to shift treatment paradigms toward durable immune reset through differentiated science in immunology and cell therapy.
🏛️ Gilead and Lakefront acquired Ouro Medicines for $1.675B to expand inflammation pipelines.
💊 Deal includes gamgertamig, a BCMAxCD3 T cell engager for severe autoimmune diseases.
🤝 Gilead leads late-stage studies while Lakefront retains early-phase development and commercialization rights.
🏛️ Gilead Sciences and Lakefront Biotherapeutics have officially completed the acquisition of Ouro Medicines to expand their inflammation pipeline.
💰 The total upfront payment for the acquisition is $1,675 million, with Lakefront and Gilead splitting this cost equally.
📈 Up to $500 million in contingent milestone payments are included in the deal structure for both parties.
💊 The primary asset acquired is gamgertamig (OM336), a BCMAxCD3 T cell engager designed for autoimmune diseases.
🎯 Gamgertamig targets severe antibody-mediated orphan diseases, specifically autoimmune hemolytic anemia and immune thrombocytopenia.
⚡ The drug has received Fast Track and Orphan Drug Designation from the U.S. FDA for its target indications.
📅 Registrational studies for gamgertamig are expected to begin as early as 2027 following current Phase 2 progress.
🤝 Gilead will lead registrational and later-stage studies, while Lakefront is responsible for ongoing Phase 1/2 clinical work.
🌍 Gilead retains sole worldwide commercialization rights outside of Keymed's territories in Greater China.
💸 Lakefront will receive tiered royalties ranging from 20% to 23% on net sales of gamgertamig.
🧬 Lakefront has also in-licensed three additional preclinical autoimmune programs from Ouro with a potential $75 million per program profit split.
📉 This transaction provides Lakefront with relief under its existing Option, License and Collaboration Agreement with Gilead.
💵 Lakefront expects to deploy at least $500 million of its available cash independently after the deal closes.
🔄 Up to $150 million of that independent cash allocation is designated for share buybacks.
💶 Lakefront's year-end 2026 cash balance is projected to be approximately €2 billion following the transaction.
🧬 Gamgertamig is in-licensed from Keymed Biosciences, which holds development rights specifically for Greater China.
🏢 Gilead continues its broader strategy of investing in differentiated science and shifting toward durable immune reset therapies.
📊 Lakefront will continue to pursue additional strategic transactions with the majority of its cash remaining post-acquisition.
Bullish Signals
Gilead acquires Ouro Medicines for $1,675M plus up to $500M milestones.
Gamgertamig (OM336) is FDA Fast Track/Orphan Drug designated T cell engager.
Registrational studies expected as early as 2027 for severe antibody-mediated diseases.
Lakefront receives 20%–23% tiered royalties on gamgertamig net sales.
Lakefront gains $500M cash relief enabling up to $150M share buybacks.
Risk Factors
$1.675B upfront payment strains liquidity and impacts priorities.
Gilead shares $1.675B cost but lacks global commercial rights.
$500M contingent milestones add financial exposure and liability.
20-23% royalties reduce Gilead's total commercial upside.
Regulatory approval timing and outcomes remain unpredictable.
Business integration risks threaten expected acquisition benefits.
Clinical trial failures could force asset write-downs.
Regulatory limitations may restrict gamgertamig use or withdraw it.
Pipeline advancement and commercialization success are uncertain.
Bullish Signals
Gilead Sciences completed the acquisition of Ouro Medicines for $1,675 million plus up to $500 million in contingent milestone payments, significantly expanding its inflammation pipeline.
The acquired asset, gamgertamig (OM336), is a first-in-class T cell engager granted both Fast Track and Orphan Drug Designation by the U.S. FDA for autoimmune hemolytic anemia and immune thrombocytopenia.
Gamgertamig is expected to enter registrational studies as early as 2027, positioning it for potential commercialization in severe antibody-mediated orphan diseases with the potential for durable disease control.
Lakefront Biotherapeutics will receive tiered royalties of 20%–23% on net sales of gamgertamig from Gilead, creating a new revenue stream for Lakefront.
The transaction provides relief under the existing Option, License and Collaboration Agreement, enabling Lakefront to deploy at least $500 million of its available cash independently, including up to $150 million for share buybacks.
Lakefront's year-end 2026 cash balance is expected to be approximately €2B, providing substantial liquidity for additional strategic transactions and capital allocation priorities.
Gilead has announced a planned $32 billion investment to further strengthen its U.S. footprint, supporting job creation and public health preparedness in the next era of discovery.
Risk Factors
The acquisition of Ouro Medicines for a total upfront payment of $1,675 million represents a significant capital outlay that could strain liquidity or impact other strategic priorities.
Gilead and Lakefront are splitting the $1,675 million cost equally, meaning Gilead is committing substantial cash to an asset that will not be commercialized by them directly outside of Keymed's territories in Greater China.
The deal includes up to $500 million in contingent milestone payments, adding further financial exposure and potential liability for both parties if development targets are met.
Lakefront will receive tiered royalties ranging from 20% to 23% on net sales, which reduces the total commercial upside for Gilead compared to owning full rights globally.
The press release explicitly lists risks including the difficulty of predicting the timing or outcome of regulatory approvals and the risk that businesses will not be integrated successfully.
There is a stated risk that Gilead may not realize the expected benefits of the Ouro Medicines acquisition or the Lakefront license and collaboration.
Forward-looking statements warn of the possibility of unfavorable results from one or more clinical trials involving gamgertamig, which could lead to asset write-downs.
Regulatory approvals for gamgertamig may be subject to significant limitations on use or withdrawal by applicable regulatory authorities.
The ability of Gilead to advance the product pipeline and successfully commercialize product candidates following the acquisition is explicitly identified as a risk.
Gilead Sciences (GILD) has recently attracted investor attention, appearing on Zacks.com's list of most searched stocks. Over the past month, GILD shares returned -4.4%, underperforming the S&P 500 composite which gained +5.4%. The broader medical-biomedical and genetics industry also declined by 2.9% during this period.
Zacks Investment Research prioritizes earnings estimate revisions to determine fair value, noting a strong correlation between these trends and short-term stock price movements. Currently, Gilead is expected to report a quarterly loss of $5.31 per share, representing a significant year-over-year decline of 364.2%. Over the last 30 days, the consensus earnings estimate has dropped by 350.5%.
Looking ahead, the consensus earnings estimate for the current fiscal year is -$0.79, down 109.7% from the prior year, while the next fiscal year's estimate stands at $9.53 with a slight upward revision of 0.6%. Revenue estimates show growth potential, with current quarter sales projected at $7.39 billion (+4.3% YoY) and full-year estimates of $30.37 billion (+3.1% YoY).
Gilead recently beat consensus estimates for both revenue and EPS in the last reported quarter, having topped expectations for the trailing four quarters consecutively. Based on these factors and the size of recent estimate changes, Zacks assigns Gilead a Rank #3 (Hold), suggesting the stock may perform in line with the broader market in the near term.
📉 Gilead shares fell 4.4% vs S&P 500's 5.4% gain last month.
💰 Quarterly loss expected at $5.31, down 364.2% year-over-year.
📈 Current quarter revenue projected at $7.39 billion, up 4.3%.
🏆 Gilead beat EPS and revenue estimates for four trailing quarters.
🎯 Zacks Rank #3 suggests stock may match broader market performance.
📉 Gilead shares returned -4.4% over the past month, underperforming the S&P 500's +5.4% gain.
📊 The company is expected to post a quarterly loss of $5.31 per share, down 364.2% year-over-year.
📈 Consensus earnings estimates for the current fiscal year are -$0.79, reflecting a 109.7% decline from the prior year.
💰 Revenue estimates indicate growth, with the current quarter projected at $7.39 billion (+4.3% YoY).
🏆 Gilead beat consensus EPS and revenue estimates in each of the trailing four quarters.
📉 The Zacks Consensus Estimate for earnings has changed by -350.5% over the last 30 days.
🎯 Zacks Rank #3 (Hold) suggests the stock may perform in line with the broader market.
Bullish Signals
Beat EPS by +7.41% and revenue by +0.95% last quarter.
Topped earnings and revenue estimates for four trailing quarters.
Revenue projected at +4.3% YoY this quarter and +6.4% next year.
Risk Factors
Expected quarterly loss of $5.31 per share.
Fiscal year estimates dropped 109.7% from prior year.
Gilead Sciences (NASDAQ: GILD) is set to present over 25 abstracts at the 2026 ASCO Annual Meeting and EHA Congress, highlighting progress in its cancer therapy pipeline. Key presentations include late-stage Phase 3 analyses for Trodelvy in first-line metastatic triple-negative breast cancer, focusing on long-term progression-free survival. Additionally, Kite will introduce manufacturing consistency data for anito-cel, an investigational CAR T-cell therapy for multiple myeloma, and showcase durability and safety results for KITE-753, an enhanced CAR T-cell therapy targeting relapsed/refractory B-cell lymphoma.
Separately, Gilead announced new Phase 3 interim data for Livdelzi in primary biliary cholangitis patients, demonstrating high and sustained normalization of the key liver marker ALP over two years of treatment with good tolerability. The company, founded in 1987 and headquartered in California, develops medicines for HIV-1, chronic hepatitis C, primary biliary cholangitis, chronic hepatitis B, and serious invasive fungal infections, having paid uninterrupted quarterly dividends for ten consecutive years.
📅 Gilead presents 25+ abstracts at ASCO and EHA conferences in May 2026.
🔬 New Trodelvy data shows long-term survival benefits for triple-negative breast cancer.
💊 Livdelzi normalizes liver markers sustainably with high safety over two years.
⚠️ Analysis suggests AI stocks may offer higher returns than Gilead currently.
📅 Gilead Sciences (NASDAQ: GILD) announced on May 21, 2026, that it will present over 25 abstracts at the 2026 ASCO Annual Meeting and EHA Congress.
🔬 Key presentations include new late-stage Phase 3 analyses for Trodelvy in first-line metastatic triple-negative breast cancer focusing on long-term progression-free survival.
🧬 For the first time, Kite will introduce manufacturing consistency data for anito-cel, an investigational CAR T-cell therapy for multiple myeloma at these conferences.
🩺 EHA updates will showcase durability and safety results for KITE-753, an enhanced CAR T-cell therapy targeting relapsed/refractory B-cell lymphoma.
💊 Gilead also announced new Phase 3 interim data showing Livdelzi achieved high and sustained normalization of the liver marker ALP in primary biliary cholangitis patients.
⏳ The Livdelzi results indicate the drug was well-tolerated over a two-year treatment period for primary biliary cholangitis patients.
🏢 Gilead Sciences, founded in 1987 and headquartered in California, develops medicines for unmet medical needs including HIV-1, hepatitis C, and serious fungal infections.
💰 The company has paid uninterrupted quarterly dividends for ten consecutive years, highlighting its status as a reliable dividend stock.
📊 The article notes that Gilead is considered one of the 10 safest dividend stocks to buy right now according to the publication's analysis.
⚠️ The text includes an investment conviction statement suggesting some AI stocks may offer higher returns and greater upside potential than GILD.
🔗 Readers are directed to additional reports on Leopold Aschenbrenner’s portfolio and Steve Cohen’s stock picks for further investment ideas.
Bullish Signals
Gilead recognized as one of 10 Safest Dividend Stocks.
Company presents 25+ abstracts showcasing cancer therapy progress.
Trodelvy Phase 3 data shows long-term progression-free survival.
Kite introduces manufacturing consistency for anito-cel CAR T-cell therapy.
EHA updates show KITE-753 durability and safety in lymphoma.
Livdelzi achieves sustained ALP normalization in primary biliary cholangitis.
Livdelzi well-tolerated over two years with strong efficacy.
Gilead paid uninterrupted dividends for ten consecutive years.
Risk Factors
Gilead risks acknowledged but other AI stocks offer higher returns faster.
Seek better AI upside? Check the report on the cheapest alternative.
Bullish Signals
Gilead Sciences is recognized as one of the 10 Safest Dividend Stocks to Buy Right Now.
The company will present over 25 abstracts at major medical conferences, showcasing significant progress in cancer therapies.
New late-stage Phase 3 analyses for Trodelvy in first-line metastatic triple-negative breast cancer are being presented, focusing on long-term progression-free survival.
Kite will introduce manufacturing consistency data for anito-cel, an investigational CAR T-cell therapy for multiple myeloma.
EHA updates will showcase the durability and safety of KITE-753, an enhanced CAR T-cell therapy targeting relapsed/refractory B-cell lymphoma.
New Phase 3 interim data shows Livdelzi achieved high and sustained normalization of a key liver marker (ALP) in primary biliary cholangitis patients.
Livdelzi was well-tolerated over two years of treatment, demonstrating strong safety and efficacy.
Gilead has paid uninterrupted quarterly dividends for ten consecutive years.
Risk Factors
The article explicitly states that while acknowledging Gilead's risk, the author believes some AI stocks hold greater promise for delivering higher returns within a shorter time frame.
The article suggests that if an investor is looking for an AI stock with more promising upside potential than GILD, they should check out a report about another 'cheapest AI stock' instead.
Gilead Sciences (NASDAQ: GILD) reported first-quarter 2026 financial results that exceeded Wall Street expectations in both revenue and earnings per share, though the company issued revised full-year guidance reflecting significant upcoming costs. Revenue for Q1 reached $6.96 billion, a 4.4% year-over-year increase compared to analyst estimates of $6.86 billion, driven by strong performance in the HIV portfolio and oncology segments. Non-GAAP adjusted earnings per share came in at $2.03, beating the consensus estimate of $1.91, while non-GAAP operating income hit $3.27 billion with a 46.9% margin, significantly higher than the estimated 44.2%. However, management lowered its full-year adjusted EPS guidance to a midpoint loss of $0.85 due to large upfront charges related to recent acquisitions, contrasting with a previous positive outlook and representing a substantial 110% decrease in projected earnings per share from the prior year's expectation.
The core HIV franchise continued to drive growth, with total HIV revenue up 10% year-over-year led by the blockbuster drug Biktarvy. The PrEP segment saw particularly explosive growth, surging 87% in the United States primarily due to the successful launch and rapid uptake of Yes2Go, a twice-yearly injectable for HIV prevention that aims to improve patient adherence compared to daily oral tablets. Management highlighted that this new modality has already achieved high prescriber adoption rates across the U.S. and Europe, positioning Gilead to maintain its leadership in the HIV market despite anticipated policy-driven pricing headwinds. Additionally, the liver disease segment received attention for Libdelzi, which more than tripled in sales in the second quarter due to strong uptake for second-line treatment of primary biliary cholangitis, although sequential declines were noted due to post-launch inventory normalization.
Oncology momentum provided another pillar of growth with Trodelvy sales increasing 37% year-over-year, benefiting from updated clinical guidelines that support broader first-line use in metastatic triple-negative breast cancer. The company also diversified its oncology and inflammation pipeline through recent acquisitions, including the completed deal for Arcellx and pending agreements for Oral Medicines and Tubulis, which introduce novel assets targeting multiple myeloma and ovarian cancer with revenue expected to ramp up in 2027 and beyond. Operating margins expanded to 37.2% from the prior year's 33.5%, attributed to disciplined expense management and the expiration of certain royalty obligations that offset higher selling and integration costs.
Looking ahead, Gilead remains focused on executing its expanding pipeline while managing the financial impact of integrating new assets and upcoming product launches such as Biclen, a once-daily oral regimen for virally suppressed patients. While the company expects continued growth in HIV treatment and prevention, as well as incremental revenue from these new therapies, management warned that increased R&D investment and transaction costs will weigh on short-term profits. The full-year non-GAAP operating margin is projected to remain high at 46.9%, but GAAP margins will be lower due to the significant one-time acquisition-related charges included in the calculation.
💊 HIV portfolio grew 10%, driven by PrEP sales and new launch pipeline.
⚡ Oncology jumped 37% from Trodelvy expansion with strong future outlook.
🤝 Recent acquisitions strengthened the pipeline but caused short-term earnings drag.
📈 Gilead Sciences reported Q1 2026 revenue of $6.96 billion, surpassing analyst estimates of $6.86 billion with a 4.4% year-over-year increase.
💰 Non-GAAP profit per share reached $2.03, significantly beating the $1.91 consensus estimate by 6.3%.
📉 Management revised full-year Adjusted EPS guidance down to -$0.85 at midpoint due to large acquisition-related IPR&D charges.
🚀 Full-year revenue guidance was lifted from $29.8 billion to $30.2 billion, indicating continued commercial strength.
🏥 The HIV portfolio grew 10% year-over-year, driven by Biktarvy and an 87% surge in U.S. PrEP sales from Yes2Go.
💊 Oncology revenue jumped 37% for Trodelvy due to expanded use in metastatic triple-negative breast cancer per new clinical guidelines.
🔬 Libdelzi sales more than tripled year-over-year in second-line primary biliary cholangitis, though they fell 11% sequentially.
🤝 Gilead strengthened its pipeline through the Arcellx acquisition and pending deals with Oral Medicines and Tubulis.
📉 Operating margin expanded to 37.2% from 33.5%, aided by royalty expirations and cost management despite integration expenses.
⚠️ The full-year negative EPS guidance is specifically due to upfront payments for recent acquisitions, excluding which underlying business remains on track.
💉 Upcoming HIV product launches include Biclen, a once-daily oral regimen, alongside the anticipated release of seven new HIV products by 2033.
🧬 Oncology growth is expected to accelerate in 2027 and beyond with differentiated candidates for ovarian cancer and multiple myeloma.
⚖️ Management warned that policy-driven pricing headwinds may modestly offset revenue gains in the HIV segment despite strong uptake.
🏢 Market capitalization stands at $166.4 billion as the company balances near-term integration costs against long-term pipeline potential.
🗣️ CEO Daniel O'Day emphasized disciplined financial management and expanding pipeline execution as central to the quarter's performance.
💼 CFO Andrew Dickinson highlighted that non-GAAP operating margin improvements were due to expense control and royalty expirations.
🚧 Integration of new assets will increase operating expenses and impact adjusted earnings per share in the near term.
📋 The company maintains leadership in HIV treatment and prevention while preparing for a diversified revenue base from new therapies.
🔮 Future clinical execution and successful market access for new therapies are critical to achieving Gilead's long-term strategic targets.
Bullish Signals
Q1 Revenue hit $6.96B, beating estimates by 1.5%.
Non-GAAP EPS reached $2.03, up 6.3% vs consensus.
Full-year guidance raised to $30.2B at the midpoint.
Operating margins expanded to 37.2%, up from 33.5%.
HIV segment grew 10% YoY driven by Biktarvy.
Oncology franchise gains momentum with Trodelvy up 37%.
Libdelzi sales tripled in primary biliary cholangitis treatment.
Acquisitions add novel assets to oncology and inflammation.
Margins improved via expense management and royalty expirations.
New launch Biclen targets virally suppressed patients.
Risk Factors
Gilead lowered full-year EPS guidance to -$0.85 midpoint due to acquisition charges.
GAAP margin lags non-GAAP of 47% amid integration costs and upfront payments.
Libtelzi sales fell 11% sequentially due to inventory drawdown and post-bolus normalization.
Policy pricing headwinds may offset future growth in HIV and oncology segments.
New therapy success from Tubulis and Arcellx introduces significant execution risk.
Regulatory delays for Trodelvy could stall revenue ramp into 2027 and beyond.
Bullish Signals
Gilead reported revenue of $6.96 billion in Q1 CY2026, beating Wall Street expectations by 1.5%.
Non-GAAP profit per share reached $2.03, which was 6.3% above analysts' consensus estimates.
The company lifted its full-year revenue guidance to $30.2 billion at the midpoint, representing a 1.3% increase.
Operating margins expanded to 37.2%, up from 33.5% in the same quarter last year.
HIV segment growth reached 10% year-over-year, driven by strong performance from Biktarvy and an 87% surge in the U.S. PrEP segment.
Oncology franchise demonstrated momentum with Trodelvy sales increasing 37% year-over-year due to growing demand in metastatic triple-negative breast cancer.
Liver disease portfolio saw Libdelzi sales more than triple year-over-year in second-line primary biliary cholangitis, showing rapid prescriber adoption.
Recent acquisitions of Arcellx and pending deals for Oral Medicines and Tubulis add novel clinical assets to the pipeline in oncology and inflammation.
Management highlighted that non-GAAP operating margins improved due to expense management and the expiration of certain royalties.
The company plans to maintain HIV leadership with upcoming launches such as Biclen, a once-daily oral regimen for virally suppressed people.
Risk Factors
Gilead lowered its full-year Adjusted EPS guidance by 110% to a negative range of -$0.85 at the midpoint, driven by significant acquisition-related IPR&D charges.
The full-year non-GAAP operating margin is 47% only after excluding one-time charges, while the GAAP margin remains much lower due to integration costs and upfront payments from recent acquisitions like Arcellx.
Sequentially, Libdelzi sales declined by 11% in the current quarter due to inventory drawdown and normalization following a Q4 bolus push.
Policy-driven pricing headwinds are expected to modestly offset future growth gains despite strong product uptake in HIV and oncology segments.
The company relies on successful clinical execution and market access for new therapies from Tubulis and Arcellx, introducing execution risk for long-term targets.
Upcoming regulatory decisions for Trodelvy and new assets will determine revenue ramp timelines into 2027 and beyond, creating potential delays if approvals stall.
Gilead Sciences (GILD) reported mixed results for its Q1 earnings call, highlighting strong operational growth that was counterbalanced by significant non-recurring charges and unusual tax effects dragging reported earnings per share into the red. The company delivered total product sales of $6.9 billion, representing a 5% year-over-year increase, while excluding revenue from the COVID drug Veklury, organic growth accelerated to 8%. This performance prompted management to raise its full-year base business sales guidance to between $29.4 billion and $29.8 billion, along with lifting total product sales expectations by approximately $400 million compared to prior forecasts.
Key segments showed robust momentum, particularly in HIV where sales rose 10% to $5.0 billion driven largely by Biktarvy and a surging PrEP business that jumped 87%. The oncology franchise also strengthened with Trodelvy sales climbing 37% to $402 million as it gained approval in triple-negative breast cancer, while the recent Tubulis acquisition added promising assets for ovarian cancer. Additionally, the liver disease portfolio saw Libdelzi generate $133 million in the quarter and capture over half of its U.S. primary biliary cholangitis market, with management projecting an IDEAL Phase 3 update later this year to support further label expansion.
Despite these operational wins, the company faces a reported loss due to large upfront transaction costs associated with recent acquisitions including Arcellx, Oral Medicines, and Tubulis, estimated at roughly $11.5 billion to $11.8 billion for the year. These expenses, combined with a highly unusual 140% to 190% effective tax rate driven by nondeductible costs, guided Gilead to a full-year non-GAAP loss per share of between -$1.05 and $-0.65, significantly distorting from an underlying EPS range of $8.45 to $8.85. However, core profitability remained intact with gross margins improving to 87% and non-GAAP diluted EPS rising 12% to $2.03.
📈 Q1 sales rose 5% YoY to $6.9B with underlying growth of 8%.
💊 HIV portfolio grew 10% while oncology sales surged 37%.
🔬 Company expanded pipeline to 47 programs amid deal activity.
💰 Gross margin hit 87% despite ~$11.7B in acquisition charges.
📈 Gilead Sciences reported Q1 total product sales of $6.9 billion, a 5% year-over-year increase, with underlying sales rising 8% excluding the COVID drug Veklury.
🚀 Management lifted its 2026 revenue outlook by $400 million, forecasting base business sales between $29.4 and $29.8 billion and total product sales from $30.0 to $30.4 billion.
💊 The HIV portfolio remained a primary growth engine with sales climbing 10% to $5.0 billion, led by Biktarvy which holds over 52% U.S. market share.
🔬 Oncology segment momentum continued with Trodelvy sales rising 37% year-over-year and the Tubulis acquisition adding a differentiated ADC platform.
💉 The liver disease portfolio saw a successful launch of Libdelzi, generating $133 million in Q1 by capturing over half of the U.S. second-line primary biliary cholangitis market.
🏦 Core profitability remained strong with product gross margin improving to 87% and non-GAAP diluted EPS rising 12% to $2.03 supported by a 47% operating margin.
💰 The company returned more than $1.4 billion to shareholders in the quarter through share repurchases and dividends, representing roughly 60% of free cash flow.
🧬 Gilead expanded its pipeline to 47 clinical programs following the closing of the Arcellx deal and pending acquisitions of Oral Medicines and Tubulis.
💸 Reported EPS faces pressure from approximately $11.5 billion to $11.8 billion in upfront intellectual property and R&D charges related to recent deals.
📉 Management guided to a full-year non-GAAP loss per share of $1.05 to $0.65 due to transaction impacts, masking an underlying EPS range of $8.45 to $8.85.
💹 Gilead expects an unusually high effective tax rate ranging from 140% to 190% for the year driven by nondeductible expenses from major acquisitions.
📊 Sequentially, total product sales fell 12% as management attributed the decline to standard Q1 seasonality and inventory drawdowns rather than demand weakness.
🛡️ Cell therapy revenue dropped to $407 million, down 12% year-over-year, amid intensified competition in new treatments across several regions.
📉 Operating expenses increased with SG&A rising 12% year over year as the company pursues strategic growth initiatives and deal expansions.
🎯 Kite unit will host anitocel, which offers differentiated efficacy for multiple myeloma and targets a $3.5 billion market opportunity in fourth-line-plus CAR-T therapies.
📅 Upcoming milestones include FDA decisions for Biclen, anitocel, and bulevirtide, alongside Phase 3 updates expected during the second half of 2026.
Gilead Sciences shares declined 1.36%, or $1.85, to close at $134.45 on Thursday as investors prepared for the company's upcoming first-quarter earnings report scheduled for release after market close on May 7th. Wall Street analysts have set a consensus EPS estimate of $1.91, which reflects a 5.5% year-over-year increase, and anticipate revenue of $6.92 billion, up 3.7% from the previous year. Despite entering the quarter following a "double beat" in its previous earnings report where it exceeded both EPS and revenue targets, Gilead's 2026 earnings guidance midpoint recently fell slightly short of market expectations. Historically, the company has demonstrated reliability by exceeding EPS estimates in every quarter over the last two years and beating revenue targets 88% of the time.
The stock decline occurs amidst significant strategic moves as Gilead aggressively pursues portfolio diversification beyond its core HIV virology franchise into oncology and immunology. The biopharmaceutical giant recently projected non-GAAP EPS for 2026 ranging from $8.45 to $8.85 and has been executing a substantial acquisition campaign, having already purchased Ouro Medicines for up to $2.18 billion in March and Arcellx Inc. for approximately $7.8 billion in February. Most notably, last month Gilead reached a definitive agreement to acquire Tubulis GmbH, a privately-held German biotechnology firm specializing in antibody-drug conjugates (ADCs), in a transaction valued at up to $5 billion. This deal is designed to strengthen Gilead's presence in cancer drug development, particularly targeting ovarian and lung cancers, with an initial cash payment of $3.15 billion and additional milestones contingent upon specific achievements.
Analysts note that while Gilead maintains a dominant position through its HIV division, it faces persistent skepticism regarding the success of its diversification efforts into oncology. The Tubulis acquisition will provide Gilead with potential new drugs for ovarian cancer and a broader platform for producing next-generation ADC drugs, which are viewed as a transformative advancement over traditional therapies that deliver potent compounds directly to tumor cells. Upon closing in the second quarter, Tubulis will operate as a dedicated ADC research division within Gilead, utilizing its Munich headquarters as a primary research hub. This strategic move positions Gilead to compete with major offerings from industry giants like AstraZeneca and Eli Lilly in the ovarian cancer sector, which Bloomberg Intelligence projects will reach $5.6 billion by 2030.
📉 Shares dropped 1.36% ahead of May 7th earnings with EPS projected at $1.91.
🤝 Gilead agreed to acquire German ADC firm Tubulis for up to $5 billion.
🎯 The deal aims to strengthen oncology portfolios amid a trend toward diversification.
📉 Gilead Sciences shares dropped 1.36% on Thursday as investors awaited the company's first-quarter earnings report scheduled for release after market close on May 7th.
💰 Wall Street analysts currently project a consensus EPS of $1.91, representing a 5.5% year-over-year increase from the previous period.
📊 Revenue estimates stand at $6.92 billion, which reflects a projected 3.7% growth compared to last year's figures.
🤝 Gilead recently signed a definitive agreement to acquire Tubulis GmbH, a German biotech firm specializing in antibody-drug conjugates (ADCs), for up to $5 billion.
💸 The deal includes an initial cash payment of $3.15 billion with an additional $1.85 billion contingent on achieving specific development milestones.
🎯 This acquisition is designed to strengthen Gilead's position in oncology by adding promising candidates in clinical trials for lung and ovarian cancers.
🚀 The Tubulis pipeline aims to compete with major players in the ovarian cancer sector, a market projected to reach $5.6 billion by 2030.
🧬 Tubulis will operate as a dedicated ADC research division within Gilead after closing, utilizing its Munich headquarters as a primary research hub.
🏢 This transaction marks Gilead's third major acquisition in the current year, following purchases of Ouro Medicines and Arcellx Inc. to diversify beyond its core virology franchise.
👨💼 CEO Daniel O'Day described the Tubulis deal as a significant milestone in Gilead's progress in oncology and ADC drug development.
📈 Historically, Gilead has demonstrated reliability by beating EPS estimates in every quarter over the last two years.
⚠️ Despite its dominant HIV division and recent M&A activity, some industry observers remain skeptical about the company's ongoing diversification efforts.
💼 In February, Gilead announced its purchase of Arcellx Inc. for approximately $7.8 billion, while in March it acquired Ouro Medicines for up to $2.18 billion.
🔬 ADC technology is viewed as a transformative advancement over traditional therapies, sparking industry consolidation similar to Pfizer's recent acquisition of Seagen.
📅 The Tubulis acquisition is slated for completion within the second quarter following the payment terms outlined in the joint statement.
Bullish Signals
Gilead on track to exceed $1.91 EPS estimate.
Company exceeded EPS estimates every quarter last two years.
Aggressive acquisitions diversify portfolio beyond core HIV business.
Stock up 10.72% year-to-date despite pre-earnings decline.
Risk Factors
Shares fell 1.36% ahead of Q1 earnings amid investor concerns.
2026 guidance missed expectations following previous double beat performance.
Company relies heavily on HIV franchise despite $13B acquisitions.
Persistent skepticism remains over successful diversification beyond HIV revenue.
$5B Tubulis deal faces up to $1.85B contingent milestone risk.
Oncology expansion faces fierce competition from rivals like AstraZeneca.
Integrating Tublis adds operational complexity to aggressive M&A strategy.
Bullish Signals
Gilead Sciences is on track to exceed analyst expectations with a consensus EPS estimate of $1.91, reflecting a 5.5% year-over-year increase.
The company has demonstrated strong historical reliability by exceeding EPS estimates in every quarter over the last two years and beating revenue targets 88% of the time.
Gilead is executing an aggressive acquisition strategy to diversify beyond its core HIV business, including deals for Tubulis GmbH ($5 billion), Ouro Medicines ($2.18 billion), and Arcellx Inc. (~$7.8 billion).
The $5 billion acquisition of Tubulis GmbH is designed to strengthen Gilead's presence in oncology by adding promising candidates for lung and ovarian cancers.
Gilead will receive an initial cash payment of $3.15 billion for the Tubulis deal, with an additional $1.85 billion contingent on development milestones.
CEO Daniel O'Day highlighted the acquisition as a significant milestone that provides a potential new drug for ovarian cancer and a broader platform for next-generation ADC drugs.
Tubulis brings established expertise in antibody-drug conjugates (ADCs), allowing Gilead to compete with major offerings from AstraZeneca and Eli Lilly in the $5.6 billion projected ovarian cancer market by 2030.
The company already markets Trodelvy for breast cancer, and the Tubulis pipeline adds new assets currently in clinical trials for solid tumors.
Year-to-date, Gilead Sciences stock is up 10.72%, despite a temporary pre-earnings decline.
Gilead has successfully positioned itself as a leader in oncology and immunology through these moves to evolve beyond its traditional virology core.
Risk Factors
Gilead Sciences shares declined 1.36% ahead of the first quarter earnings release, signaling potential investor concern despite a year-to-date gain.
The company's 2026 earnings guidance midpoint fell slightly short of market expectations following its previous 'double beat', indicating growing uncertainty about growth projections.
Despite an aggressive acquisition spree totaling over $13 billion in just three deals this year (Arcellx, Ouro Medicines, and Tubulis), the company remains heavily dependent on its core virology franchise.
Investors face persistent skepticism regarding Gilead's ability to successfully diversify beyond its HIV division, which has historically been the primary driver of revenue.
The $5 billion acquisition of Tubulis GmbH is contingent on achieving specific development milestones, with only an initial $3.15 billion paid in cash and up to $1.85 billion remaining at risk.
The rapid expansion into oncology targets a highly competitive landscape dominated by major rivals like AstraZeneca and Eli Lilly in the ovarian cancer market.
Integrating Tubulis as a dedicated ADC research division within Gilead's Munich hub adds complexity to operations amidst an already aggressive M&A campaign.
Gilead Sciences, headquartered in Foster City, California, announced layoffs affecting 108 workers at its Redwood City offices shortly after completing the acquisition of Arcellx Inc. for approximately $7.8 billion in early April 2020. The positions impacted include roles in manufacturing, quality assurance, marketing, sales, and clinical development, specifically noting that twelve senior directors and eleven vice presidents are among those losing their jobs. These employees will lose their jobs between June 30, 2021, and April 30, 2027, following the filing of a Worker Adjustment and Retraining Notification (WARN) with the California Employment Development Department.
In addition to the Redwood City reductions, Gilead let go of 84 employees in Rockville, Maryland, as reported by the state's Department of Labor, and terminated another 34 positions at its Oceanside campus on March 27. A company spokesperson attributed these actions to integration following the Arcellx transaction, emphasizing that while such decisions are taken with difficulty, the focus remains on supporting employees during the transition. The executive vice president of Kite Pharma noted that the company's focus has shifted toward executing the acquisition and preparing to bring anito-cel patients into treatment.
This round of layoffs occurs within a broader trend of consolidation and job cuts in the Bay Area biotech sector, particularly following an influx of investment during the pandemic which recently gave way to mass layoffs, slashed drug pipelines, and bankruptcies among industry peers like Pfizer, which abandoned its South San Francisco office.
📉 Gilead announces 108 layoffs at Redwood City within seven months of prior cuts.
💰 Cuts follow a $7.8 billion Arcellx acquisition aimed at expanding cell therapy access.
🏢 Affected roles include manufacturing, sales, and senior leadership across multiple corporate sites.
📉 Gilead Sciences has announced 108 layoffs at its Redwood City offices, just seven months after a previous round of cuts involving 104 workers.
⏳ The company filed a WARN notice covering job losses scheduled to occur between June 30 and April 30, 2027.
🏢 Affected roles span manufacturing, quality assurance, marketing/sales, clinical development, as well as upper-level leadership with 12 senior directors and 11 vice presidents losing positions.
📍 The biotech giant also recently released 84 employees from its Rockville, Maryland facility and 34 staff from its Oceanside campus.
💰 Elizabeth Baxter, a spokesperson for Gilead, stated that the departures are part of integration processes following the closure of the Arcellx transaction.
🔎 Gilead completed its acquisition of Arcellx Inc. on April 28 for approximately $7.8 billion to gain access to cell therapies for cancer and autoimmune diseases.
🚑 Cindy Perettie, EVP of Kite Pharma, emphasized a focus on speed and discipline as the company prepares to bring its anito-cel therapy to patients.
📉 The Bay Area biotech sector has been experiencing a steady decline recently, characterized by mass layoffs, slashed drug pipelines, and bankruptcies.
💊 Gilead is best known in this broader context for developing treatments for COVID-19 and HIV.
⚠️ This wave of hiring cuts comes against the backdrop of Pfizer abandoning its South San Francisco office due to industry downturns.
Bullish Signals
Gilead acquires Arcellx for approx $7.8 billion.
Deal adds cancer and autoimmune cell therapies.
Kite Pharma leadership confident in quick execution.
Gilead remains a major COVID-19 and HIV developer.
Risk Factors
108 workers laid off in Redwood City within seven months.
LAWN filing indicates instability until April 2027.
Cuts include 12 senior directors and 11 vice presidents.
Total recent layoffs reach 160 across Rockville and Oceanside.
Gilead Sciences recently completed its acquisition of Arcellx Inc., paying approximately $7.8 billion for an approximately 77% share of the company.
The acquisition brings promising cell therapies for cancer and autoimmune diseases to Gilead's portfolio.
Cindy Perettie, executive vice president and global head of Kite Pharma, expressed confidence in executing quickly and with discipline to bring the anito-cel treatment to patients.
Gilead is a major developer of COVID-19 and HIV treatments, maintaining its status as a leading biopharmaceutical player.
Risk Factors
Gilead Sciences is laying off 108 workers from its Redwood City offices just seven months after its last major round of layoffs in November.
The company recently filed a Worker Adjustment and Retraining Notification covering an extensive period from June 30 to April 30, 2027, indicating long-term instability.
The latest cuts include 12 senior directors and 11 vice presidents, representing significant leadership turnover during a strategic acquisition integration.
Gilead has already laid off 84 employees in Rockville, Maryland, and an additional 34 at its Oceanside campus recently.
These reductions come after Gilead paid approximately $7.8 billion for a 77% stake in Arcellx Inc., raising concerns about the costs of integration versus retained talent.
The broader biotech sector in the Bay Area is described as being on a 'steady decline,' with mass layoffs, slashed drug pipelines, and bankruptcies occurring over the past few years.
Biotech giant Gilead Sciences (GILD) is preparing to report first-quarter results on May 7 following the market close, with Zacks Consensus Estimates projecting sales of $6.89 billion and earnings of $1.89 per share. Recent analyst sentiment has slightly tempered long-term growth expectations, with 2026 earnings per share estimates decreasing to $8.62 from $8.66 over the past 60 days, and 2027 estimates falling to $9.62 from $9.63. Historically, GILD has a solid earnings track record, beating estimates in three of its last four quarters with an average surprise of 4.76%, including a beat of 1.64% in the most recently reported quarter. The company currently holds a Zacks Rank #3 and an Earnings ESP of +0.33%.
The core of GILE's growth strategy continues to revolve around its market-leading HIV franchise, which saw significant support from recent product approvals and strong sales figures. Its flagship therapies, Biktarvy and Descovy, remain dominant, with Biktarvy capturing over 52% of the U.S. HIV treatment market and Descovy holding more than 45% of the U.S. pre-exposure prophylaxis (PrEP) market, roughly 80% of which is for HIV prevention. A key new driver is Yeztugo (lenacapavir), a twice-yearly injectable for HIV prevention, which generated $96 million in Q4 sales and is projected to reach $150 million in 2025 with an anticipated revenue of approximately $800 million in 2026. Consequently, Gilead expects total HIV sales to grow about 6% year over year, though this guidance factors in pricing pressures from government agreements and potential Affordable Care Act changes that could reduce growth by roughly two percentage points.
Beyond HIV, GILE's diversified portfolio includes liver disease treatments like Livdelzi for primary biliary cholangitis, which has seen increased demand, and oncology assets such as Trodelvy for metastatic breast cancer, which continues to gain market share. While cell therapy products like Yescarta and Tecartus are expected to show a decrease in sales due to competitive headwinds in the U.S. and Europe, innovation remains strong with positive data emerging from ARTISTRY-1 and ARTISTRY-2 studies for HIV treatments. Despite outperforming both its sector and the S&P 500 by 6.6% year to date, GILD trades at a forward P/E ratio of 14.62x, which is above its historical mean but below the broader large-cap pharma industry average of 16.18x. Investors will be watching closely as the company navigates competition from peers like GSK plc, whose long-acting HIV injectables are seeing strong demand, while Gilead leverages its scale and pipeline depth to maintain its status as a safe haven in the biotechnology sector.
📅 Gilead reports Q1 earnings on May 7 with sales estimated at $6.89B.
🦠 HIV franchise dominates revenue with top drugs holding major US market shares.
💊 New therapies like Livdelzi and Yeztugo are driving diversified growth.
📅 Gilead Sciences (GILD) is set to report Q1 earnings on May 7 after market close, with consensus estimates for sales at $6.89 billion and EPS at $1.89.
⬇️ Analyst estimates for 2026 and 2027 have slightly declined recently, dropping to $8.62 and $9.62 per share respectively over the past 60 days.
📈 The company has a strong track record of beating earnings estimates in three of the last four quarters with an average surprise of 4.76%.
💡 Gilead currently holds a Zacks Rank #3 (Hold) and has a positive Earnings ESP of +0.33%, indicating potential for an earnings beat.
🦠 The HIV franchise remains the core driver, with Biktarvy accounting for over 52% market share in the U.S. treatment market as the top revenue generator.
💉 Descovy continues to lead the prevention market with a 45% share in the U.S., where roughly 80% of sales are attributed to PrEP usage.
🆕 The newly approved injectable HIV-1 capsid inhibitor, Yeztugo (lenacapavir), showed encouraging early uptake with $96 million in Q4 sales and projected revenues of ~$800 million for 2026.
📊 Management projects total HIV sales growth of approximately 6% year-over-year, despite pricing pressures from government drug agreements expected to reduce growth by two percentage points.
💊 The Liver Disease portfolio saw likely increases in Q1 sales driven by strong demand for Livdelzi (seladelpar) for treating primary biliary cholangitis.
📉 Cell Therapy product sales face headwinds due to competition, causing estimates to decrease, with the consensus estimate pinned at $432 million for the quarter.
🎯 Trodelvy is gaining market share in second-line metastatic breast cancer and has received approval for pre-treated HR+/HER2- metastatic breast cancer, with potential first-line approval expected in 2026.
💼 Gilead’s strategic moves include investing heavily in R&D and sales/marketing to support commercial launches of new therapies like Yeztugo and Livdelzi.
📈 GILD shares have outperformed the sector and S&P 500 year-to-date, rising 6.6% compared to the industry's 3.2% growth.
💰 Currently trading at a forward P/E ratio of 14.62x, which is above the company's historical mean but below the large-cap pharma industry average of 16.18x.
🌍 Positive data from recent phase III studies evaluating bictegravir and lenacapavir combinations serves as a significant boost for Gilead’s HIV treatment pipeline.
Bullish Signals
GILD has a strong track record of earnings beats in three of the trailing four quarters, delivering an average surprise of 4.76%.
The company holds a Zacks Rank #3 (Hold) and a positive Earnings ESP of +0.33%, which increases the odds of another earnings beat.
Flagship HIV therapies Biktarvy and Descovy continue to fuel top-line growth, with Biktarvy accounting for over 52% of the U.S. treatment market.
The FDA approval for Yeztugo (lenacapavir) provides a significant boost to the HIV portfolio, with management projecting revenues of approximately $800 million in 2026.
Initial uptake for Yeztugo has been encouraging, generating $96 million in fourth-quarter sales and $150 million in 2025.
Total HIV sales are expected to grow approximately 6% year over year, driven by treatment and prevention portfolios.
New product Livdelzi is driving increased sales in the Liver Disease franchise due to higher demand for treating primary biliary cholangitis.
Positive data from phase III ARTISTRY-1 and ARTISTRY-2 studies serves as a significant boost for the company's HIV development pipeline.
The anti-cancer drug Trodelvy continues to gain market share in the second-line setting for metastatic breast cancer, with potential first-line approval expected in 2026.
GILD's shares have outperformed the sector and the S&P 500, rising 6.6% year to date compared to the industry's 3.2% growth.
Risk Factors
Forward earnings estimates have declined over the past 60 days, dropping to $8.62 per share for 2026 from $8.66 and $9.62 for 2027 from $9.63.
Company growth guidance incorporates pricing pressure from government drug-pricing agreements on legacy products and potential channel mix shifts tied to Affordable Care Act changes, reducing expected growth by roughly two percentage points.
Cell Therapy product sales have likely decreased in the first quarter due to competitive headwinds in both the United States and Europe affecting Yescarta and Tecartus.
Veklury sales are described as highly variable, indicating unpredictability in a key revenue segment.
R&D expenses might have increased in the first quarter, along with higher SG&A expenses reflecting investments to support commercial launches.
The stock trades at a forward P/E of 14.62x, which is higher than its historical mean of 11.55x, potentially presenting a valuation premium compared to the company's own history.
Kymera Therapeutics (KYMR) reported first-quarter 2026 earnings that surpassed analyst expectations, driven largely by significant revenue growth from its collaboration with Gilead Sciences (GILD). The company posted a loss of 71 cents per share compared to a Zacks Consensus Estimate of a loss of 89 cents, marking an improvement over the year-ago quarter's loss of 82 cents. Quarterly revenues reached $34.37 million, representing a 55.5% year-over-year increase and exceeding the consensus estimate of $11 million. Notably, all collaboration revenue recognized in the quarter came from Gilead; the company also secured a key development by having Gilead exercise its option to exclusively license KT-200, a first-in-class oral CDK2 molecular glue degrader. This exercise triggers a $45 million milestone payment expected in the second quarter and sets eligibility for approximately $700 million in additional milestone payments.
Despite the revenue gains, operating expenses increased as the company scaled its clinical execution and discovery engine. Research and development expenses rose 22.3% year over year to $98.2 million, reflecting higher spending on the STAT6 program, platform technologies, and organizational growth. General and administrative expenses also climbed 25.1% to $20.4 million due to increased legal fees, professional services, and personnel costs associated with being a public company. Nevertheless, Kymera ended the quarter with $1.55 billion in cash, cash equivalents, and investments, providing an operating runway expected to extend into 2029.
The financial performance is underpinned by substantial progress across its pipeline, particularly with KT-621, an investigational once-daily oral STAT6 degrader for type II inflammatory diseases. The company is advancing KT-621 in two parallel phase IIb trials: the BROADEN2 study for atopic dermatitis and the BREADTH study for moderate-to-severe eosinophilic asthma. Regulatory momentum has been bolstered by FDA Fast Track designations for KT-621 in both conditions. Additionally, the company is progressing KT-579, an IRF5 degrader for autoimmune diseases, which recently received IND clearance and began dosing in a first-in-human phase I study, while its partner program with Sanofi, KT-485/SAR447971, is expected to enter clinical trials in 2026.
Market reaction to the results has been positive, with KYMR shares gaining 5.3% year-to-date against the industry's 1.1% decline. Management emphasized that their cash resources are sufficient to fund ongoing Phase IIb execution for KT-621, advance KT-579 into early proof-of-concept planning, and support continued pipeline expansion. The company reiterated that the investment thesis centers on pipeline execution in targeted protein degradation, led by KT-621, which is currently in phase II trials for dermatology and respiratory indications with data anticipated by mid-to-late 2027.
📈 Q1 revenue surged 55.5% to $34.37M, driven entirely by Gilead collaboration.
💸 Spending rose to $98.2M on the pipeline while cash remains at $1.55B.
🔬 Lead drug KT-621 received FDA Fast Track status for asthma treatment.
💰 A pending $45M Gilead milestone payment is expected in the second quarter.
📉 Shares rose 5.3% year-to-date, outperforming the broader industry decline.
💰 Kymera Therapeutics posted a first-quarter 2026 loss of 71 cents per share, narrowing from a loss of 82 cents in the year-ago quarter.
📈 Quarterly revenues reached $34.37 million, representing a 55.5% year-over-year increase that significantly exceeded analyst estimates.
🤝 All revenue recognized in Q1 was driven exclusively by the collaboration with Gilead Sciences, where upfront payments were fully recognized.
💸 Operating expenses rose as the company increased investment in its clinical pipeline and discovery engine to $98.2 million.
💰 General and administrative costs increased 25.1% to $20.4 million due to higher legal fees and personnel costs associated with being a public company.
💵 Kymera ended the quarter with $1.55 billion in cash, providing an operating runway expected to last into 2029.
🤝 Gilead exercised its option to exclusively license KT-200, triggering a $45 million milestone payment expected in the second quarter.
💰 The partnership agreement with Gilead includes eligibility for approximately $700 million of additional milestone payments.
🔬 KT-621 remains the company's lead program, an oral STAT6 degrader advancing in two parallel Phase IIb trials for atopic dermatitis and asthma.
⚕️ The FDA granted Fast Track designation to KT-621 for moderate-to-severe eosinophilic asthma in addition to its prior designation for atopic dermatitis.
🧬 Kymera is progressing KT-579, an oral IRF5 degrader for autoimmune diseases, which recently received IND clearance for a first-in-human Phase I study.
🔬 KT-485/SAR447971, a partner program with Sanofi targeting IRAK4, completed IND-enabling studies and is expected to enter clinical trials in 2026.
📈 Year-to-date, KYMR shares have gained 5.3% compared to the industry's 1.1% decline.
🏆 The company reiterated that its cash resources are sufficient to fund ongoing Phase IIb execution and pipeline expansion for later-stage development.
⭐ Zacks analyst ranks Kymera Therapeutics with a #3 (Hold) rating.
Bullish Signals
Kymera Therapeutics posted Q1 earnings that topped estimates with a loss of 71 cents per share, which is narrower than the consensus estimate of 89 cents.
Quarterly revenues surged to $34.37 million, representing a 55.5% year-over-year increase and surpassing the Zacks Consensus Estimate of $11 million.
The company's partnership with Gilead Sciences (GILD) was a primary driver of revenue, resulting in a fully recognized upfront payment that sets the stage for milestone-driven variability.
Management received a decision from Gilead to exercise its option to exclusively license KT-200, triggering an expected $45 million milestone payment receivable in Q2 and eligibility for roughly $700 million in additional milestones.
Kymera exited the quarter with $1.55 billion in cash, cash equivalents, and investments, providing a supported operating runway into 2029.
The FDA granted Fast Track designation to KT-621 for moderate-to-severe eosinophilic asthma, complementing its existing Fast Track status in atopic dermatitis.
Year to date, KYMR shares gained 5.3% against the industry's 1.1% decline, outperforming peers despite market headwinds.
KT-621 is advancing in two parallel Phase IIb trials in dermatology and respiratory indications with enrollment expected to be completed in 2026.
Risk Factors
Kymera Therapeutics reported a net loss of 71 cents per share in Q1 2026, which, while better than the consensus estimate of an 89 cent loss, still reflects negative earnings.
R&D expenses surged to $98.2 million, a 22.3% year-over-year increase driven by scaling clinical pipeline investments and growth in the R&D organization.
General and administrative expenses rose 25.1% to $20.4 million due to increased personnel, facility costs, and legal fees associated with being a public company.
The upfront payment from the Gilead partnership has been fully recognized, meaning future collaboration revenue will be entirely dependent on milestone payments rather than recurring income.
All Q1 collaboration revenues came solely from Gilead (GILD), creating concentration risk as no other significant partner revenue streams were recognized in the quarter.
The company currently holds a Zacks Rank #3 (Hold), which is a neutral-to-negative rating compared to competitors like Castle Biosciences that hold a #1 Strong Buy rank.
Clinical trial timelines for lead assets KT-621 and KT-579 extend into 2026 and 2027, delaying potential returns on the heavy R&D spend before commercialization.
Kymera's cash runway extends to 2029, which is a long-term commitment that exposes the company to valuation pressure if clinical success rates fall short of expectations.
A bullish thesis on Gilead Sciences, Inc. (GILD) has been highlighted by analyst Trevor Young, who characterizes the biopharmaceutical company as a "Safe Atom" within the Barbell Strategy due to its stability and predictable cash flow. As of April 20th, GILD shares traded at $135.87 with trailing and forward price-to-earnings ratios of 20.04 and 15.50, respectively. The company maintains a strong financial profile supported by an HIV market share consistently above 70%, returns on equity around 42%, and a stable debt-to-equity profile. GILD is noted for its low volatility, with a beta well below the S&P 500, which provides investors with steady returns even during turbulence in high-risk growth sectors.
The investment case relies on two primary catalysts: the rollout of Lenacapavir and the maturation of its oncology business through Kite Pharma. As of March 2026, Gilead offers a quarterly dividend of $0.82 per share, yielding approximately 2.4% with a payout ratio under 50%, allowing the firm to fund R&D while maintaining financial flexibility. Lenacapavir, a twice-yearly long-acting HIV therapy, is expected to defend and extend market leadership against competitors like ViiV, while the Kite Pharma acquisition aims to diversify revenue beyond HIV without relying on speculative breakthroughs. This strategy supports a concept referred to as "paid patience," where investors wait for these catalysts to unlock additional upside while earning dividends.
Gilead's fundamentals have improved significantly since previous coverage in February 2025, during which Disruptive Analytics noted a fair value estimate of $115 amid headwinds such as the Inflation Reduction Act and a lower COVID-related hospitalization rate. Since that report, GILD's stock price has appreciated by approximately 30.54%. However, investor interest in the stock has been tempered relative to AI-driven opportunities; Gilead is not included on lists of popular stocks among hedge funds, with only 71 portfolios holding the shares at the end of the fourth quarter compared to 61 in the previous quarter. While the article acknowledges GILD's potential as a cornerstone for conservative portfolios, it concludes by suggesting that certain AI stocks may offer higher returns and greater upside potential over a shorter time frame.
💼 Gilead offers stable cash flow and a 2.4% dividend yield as a "safe atom" in biotech portfolios.
📈 Stock price up 30.54% since February, trading at $135.87 with forward P/E of 15.50.
💊 Revenue driven by HIV leadership and Kite Pharma's oncology growth diversifies business streams.
⚠ Some investors favor AI stocks for higher returns over Gilead's conservative growth approach.
🔬 Gilead Sciences, Inc. (GILD) is described as a "Safe Atom" within the Barbell Strategy, offering stability and predictable cash flow in a volatile biotech sector.
💰 Trading at $135.87 as of April 20th, the stock has a trailing P/E of 20.04 and a forward P/E of 15.50 according to Yahoo Finance.
📊 Gilead's quarterly dividend is approximately $0.82 per share with a yield near 2.4%, supported by a payout ratio under 50% as of March 2026.
🛡️ The company maintains low volatility with a beta below the S&P 500, acting as ballast for portfolios seeking steady returns during market turbulence.
💊 Revenue stability is underpinned by HIV market leadership, with share consistently above 70% and generating utility-like cash flow.
🚀 Key catalysts include the rollout of Lenacapavir, a twice-yearly long-acting HIV therapy intended to defend and extend market leadership against competitors like ViiV.
🧬 Oncology growth is expected to diversify revenue through the Kite Pharma acquisition, which delivers steady high-margin expansion without relying on speculative breakthroughs.
⚖️ Financial fundamentals remain robust with strong returns on equity around 42% and a stable debt-to-equity profile.
📉 Previous analysis highlighted revenue headwinds from the Inflation Reduction Act and a strong dollar, noting a fair value estimate of $115 in February 2025.
📈 Since that earlier coverage, GILD's stock price has appreciated by approximately 30.54%, reflecting a bullish outlook on disciplined capital allocation.
💸 While Gilead provides essential cash flow for conservative portfolios, the text notes it is not classified as a high-risk "moonshot" investment vehicle.
📉 Hedge fund sentiment shows GILD held in 71 portfolios at the end of Q4 compared to 61 previously, though some funds prioritize AI stocks for higher potential returns.
⚠️ The article concludes that while Gilead is a strong contender, certain AI stocks are deemed to hold greater promise for delivering higher returns over shorter time frames.
🔗 Readers are directed to separate reports on AI stocks claimed to have massive upside potential, distinct from the conservative growth thesis of Gilead.
Bullish Signals
Forward P/E of 15.50 is more attractive than trailing P/E of 20.04.
Stable dividend yield of 2.4% with payout ratio under 50% enables R&D investment.
Low beta provides low-volatility ballast and steady returns during market turbulence.
Lenacapavir rollout defends HIV market leadership against competitors like ViiV.
HIV market share consistently above 70% demonstrates entrenched core leadership.
On oncology segment delivers high-margin expansion through Kite Pharma acquisition.
Strong returns on equity around 42% reflect robust fundamental performance.
Stock appreciated 30.54% since February 2025, indicating positive investor sentiment.
Revenue hurt by inflation laws, strong dollar, and low COVID hospitalizations.
Hedge fund interest declined: 61 portfolios vs. 71 previously.
Stock already rose 30.54%, limiting future upside potential.
Not among 40 most popular hedge fund stocks.
AI stocks seen as more efficient for short-term returns.
Bullish Signals
Gilead Sciences, Inc. trades at a forward P/E of 15.50, which is more attractive than its trailing P/E of 20.04.
The company maintains a stable dividend yield of approximately 2.4% with a payout ratio under 50%, providing financial flexibility for R&D investments.
GILD's beta is well below the S&P 500, offering low-volatility ballast that provides steady returns during market turbulence.
The rollout of Lenacapavir, a twice-yearly long-acting HIV therapy, positions Gilead to defend and extend its market leadership against competitors like ViiV.
Gilead's HIV market share remains consistently above 70%, demonstrating entrenched leadership in the core therapeutic area.
The oncology segment through the Kite Pharma acquisition is delivering steady, high-margin expansion, diversifying revenue beyond a single therapeutic area.
Gilead maintains strong returns on equity around 42%, reflecting robust fundamental performance.
Since February 2025 coverage, GILD's stock price has appreciated by approximately 30.54%, indicating positive investor sentiment.
Risk Factors
Gilead Sciences is criticized for slower top-line growth relative to AI-driven drug discovery startups, presenting a competitive disadvantage in the evolving biotech landscape.
Revenue headwinds from the Inflation Reduction Act, a strong dollar, and lower COVID-related hospitalizations previously impacted Gilead's performance.
Hedge fund interest in Gilead is declining, with only 61 portfolios holding GILD at the end of the fourth quarter compared to 71 in the previous quarter.
The stock price appreciation of approximately 30.54% since previous coverage suggests Gilead may have already priced in many bullish catalysts, limiting future upside potential compared to alternative AI stocks.
Gilead is not on the list of the 40 Most Popular Stocks Among Hedge Funds, indicating a lack of institutional conviction relative to other market leaders.
Management and analysts suggest investors should consider AI stocks that have greater promise for delivering higher returns within a shorter time frame, implicitly questioning Gilead's growth efficiency.
Gilead Sciences (GILD) is set to report quarterly earnings for the period ended March 2026, with Wall Street anticipating a year-over-year increase in both revenue and earnings per share. Analysts project quarterly revenues of $6.89 billion, representing a 3.4% increase from the prior year, while estimated EPS stands at $1.89, marking a 4.4% growth. These figures are expected to be released on May 7, with positive results potentially driving the stock higher, though misses could lead to downward pressure on the share price.
Ahead of the release, the consensus EPS estimate has seen slight revisions downward by 0.33% over the last 30 days, yet the Zacks Earnings Expected Surprise Prediction (ESP) model indicates a positive reading of +0.33%. This metric compares the most accurate recent estimates against the broader consensus, suggesting that analysts with the latest data have become bullish on Gilead. The company currently holds a Zacks Rank of #3 (Hold), and historically, stocks combining a positive ESP with ranks of 1 through 3 beat earnings expectations roughly 70% of the time.
Gilead has a strong track record regarding these projections, having beaten consensus EPS estimates in three out of its last four quarters. For the final reported quarter before this one, the company posted actual earnings of $1.86 per share against an expected $1.83, resulting in a positive surprise of 1.64%. While earnings beats are not the sole driver of stock price movement due to other business factors, Gilead appears to be a compelling candidate for beating consensus estimates based on current analyst sentiment and historical performance, with results likely influencing both immediate stock price action and future earnings expectations during management's discussion.
🗓 Gilead reports March 2026 earnings on May 7 with $1.89 EPS expected.
💰 Revenue forecasts $6.89B, but recent consensus estimates dropped slightly.
🚀 Positive Earnings ESP and history suggest a high probability of beating estimates.
⚠ Other factors beyond earnings can still significantly impact the stock price.
📅 Gilead Sciences (GILD) is scheduled to report its quarter ended March 2026 on May 7.
📈 Analysts anticipate quarterly earnings of $1.89 per share, representing a 4.4% year-over-year increase.
💰 Expected revenue stands at $6.89 billion, marking a 3.4% growth compared to the prior-year quarter.
📉 The consensus EPS estimate has been adjusted downward by 0.33% over the last 30 days.
🔍 Zacks Investment Research's Earnings ESP model indicates a positive reading of +0.33% for Gilead.
🤖 This model compares the Most Accurate Estimate against the consensus to predict potential earnings deviations.
🚀 A positive Earnings ESP combined with a Zacks Rank #3 suggests a high probability of beating estimates.
📊 Historical data shows the company beat EPS consensus three times out of the last four quarters.
👣 In the last reported quarter, Gilead delivered a surprise with earnings of $1.86 versus an expectation of $1.83.
⚠️ While an earnings beat increases success odds, other factors can influence stock price movement regardless.
🏥 Gilead operates primarily in the HIV and hepatitis C drug markets as a key pharmaceutical player.
🔭 The upcoming results will be critical for determining the sustainability of near-term stock price changes.
💡 Analysts have recently become more bullish on Gilead, raising their Most Accurate Estimate above consensus.
📉 A negative Earnings ESP or a low Zacks Rank generally makes predicting an earnings miss more difficult than a beat.
🛠️ Investors are advised to use the Zacks Earnings ESP Filter before making trading decisions around the report date.
Bullish Signals
Consensus earnings forecast $1.89/share, up +4.4% year-over-year.
Revenue projected at $6.89 billion, a +3.4% increase.
Most Accurate Estimate recently increased relative to consensus.
Zacks Earnings ESP model shows positive +0.33% reading.
Company beats EPS estimates 3 of the last 4 quarters.
Risk Factors
Gilead EPS estimates down 0.33% over last 30 days.
Zacks Rank #3 limits model predictive power compared to buys.
Earnings beat may not lift stock if other conditions fail.
Bullish Signals
Gilead Sciences is expected to deliver a year-over-year increase in earnings, with consensus estimates projecting quarterly earnings of $1.89 per share representing a +4.4% growth.
Revenue is forecasted at $6.89 billion, which reflects a strong 3.4% increase from the same quarter last year.
Analysts are becoming more bullish on the company, as the Most Accurate Estimate has recently increased relative to the consensus estimate.
The Zacks Earnings ESP model indicates a positive reading of +0.33%, which is a strong predictor that Gilead will likely beat its earnings consensus.
Gilead holds a Zacks Rank of #3 (Hold), and research shows that companies with positive Earnings ESP combined with Rank #1, #2, or #3 produce a positive surprise nearly 70% of the time.
The company has a strong track record, having beaten consensus EPS estimates three out of the last four quarters.
Risk Factors
The consensus EPS estimate for Gilead has been revised down 0.33% over the last 30 days, reflecting a collective bearish reassessment by analysts ahead of the report.
Although Gilead beat estimates three times in the last four quarters, a negative Earnings ESP reading is explicitly stated to not be indicative of an earnings miss, introducing uncertainty regarding future predictive accuracy.
The company carries a Zacks Rank of #3 (Hold), which the text notes limits the predictive power of its Earnings ESP model compared to 'Strong Buy' or 'Buy' ratings.
Investors are warned that even an earnings beat may not be sufficient to move the stock higher if other business conditions disappoint investors, indicating potential downside catalysts unrelated to earnings numbers.
Gilead Sciences, Inc. (GILD) is currently facing underperformance relative to broader market benchmarks, having declined 8.2% over the past month compared to the S&P 500's gain of 12.2%, while its specific medical and genetic industry sector fell by 3%. The article emphasizes that fundamental earnings projections are more critical for long-term value than short-term rumors or media releases. Analyst consensus estimates indicate a quarterly earnings per share (EPS) of $1.89, representing a 4.4% increase from the previous year, while fiscal year full-year EPS estimates stand at $8.62, up 5.8% year-over-year. Looking further ahead to the next fiscal year, earnings are projected at $9.62, marking an anticipated 11.6% growth rate.
Revenue analysis reveals a consensus sales estimate for the current quarter of $6.89 billion, which suggests a 3.4% year-over-year increase, while full-year and next fiscal year sales are estimated at $30.15 billion and $32.36 billion respectively, with projected growth rates of 2.4% and 7.4%. Gilead recently reported actual quarterly revenues of $7.93 billion and EPS of $1.86, both figures exceeding the consensus estimates by 4.63% and 1.64% respectively. Historically, the company has surpassed consensus estimates for earnings three out of four recent quarters and revenue estimates three times over that same period.
Valuation analysis utilizing Zacks metrics assigns Gilead a 'B' grade on its Value Style Score, indicating that the stock is currently trading at a discount relative to its peers despite an impressive track record of audited financials. However, the proprietary Zacks Rank tool assigns the company a #3 rating, which suggests a neutral outlook where the stock is expected to perform in line with the broader market rather than significantly outperforming or underperforming. These factors collectively suggest that while earnings growth and recent beat performance are positive, the immediate forward price momentum may remain moderate based on current analyst revisions.
🚀 Earnings expected to rise 4.4% this quarter and 11.6% next year.
⚖ Traded at a discount with a Zacks Rank of #3 (Hold).
📉 Gilead Sciences (GILD) shares fell -8.2% over the past month, underperforming the S&P 500's +12.2% gain and its industry peers' -3% loss.
💰 The company is projected to report quarterly earnings of $1.89 per share for the current quarter, representing a +4.4% increase from the year-ago period.
📊 Consensus estimates show a +5.8% year-over-year growth trajectory for the current fiscal year based on a consensus EPS of $8.62.
🚀 Forward-looking estimates indicate an impressive +11.6% growth for next fiscal year with a projected consensus EPS of $9.62.
📉 Recent analyst activity shows slight downward adjustments, with consensus earnings estimates dropping -0.3% over the last 30 days.
🏢 Reported quarterly revenues reached $7.93 billion, exceeding the consensus estimate of $7.57 billion by +4.63%.
📈 The company has a strong track record of beating expectations, surpassing consensus EPS and revenue estimates three times each over the last four quarters.
💵 Consensus sales forecasts project current fiscal year revenue of $30.15 billion (+2.4% growth) and next fiscal year at $32.36 billion (+7.4% growth).
⚖️ Gilead carries a Zacks Value Style Score of B, indicating the stock is currently trading at a discount relative to its peers.
🛡️ Despite strong fundamental earnings growth projections, the proprietary Zacks Rank tool assigns a rating of #3 (Hold) for near-term performance.
💡 The Zacks methodology emphasizes that changes in earnings estimate revisions are a primary driver of fair value and subsequent stock price movements.
📉 The company's recent underperformance contrasts with its positive long-term growth metrics and historical ability to beat consensus targets.
🔍 Analysts note that while fundamental facts drive long-term buy-and-hold decisions, short-term stock direction often follows earnings estimate trends.
Bullish Signals
Revenues hit $7.93 billion with +4.7% growth.
Beat estimates with +4.63% revenue and +1.64% EPS surprise.
Surpassed earnings and revenue consensus three times in four quarters.
Fiscal year sales projected at $30.15 billion (+2.4% growth).
Next fiscal year earnings expected at $9.62 (+11.6% growth).
Zacks Value Style Score rates stock a 'B' trading at discount.
Risk Factors
Shares down 8.2% vs S&P 500's +12.2% and industry.
Earnings and revenue estimates revised downward recently.
Current EPS of $1.86 trails prior year's $1.90.
Grade 'B' signals insufficient undervaluation for aggressive buying.
Bullish Signals
Gilead reported revenues of $7.93 billion in the last quarter, representing a year-over-year growth of +4.7%.
The company beat consensus estimates with a revenue surprise of +4.63% and an EPS surprise of +1.64%.
Over the last four quarters, Gilead surpassed consensus earnings estimates three times and topped revenue estimates three times.
Consensus sales for the current fiscal year are estimated at $30.15 billion with a projected year-over-year increase of +2.4%.
The consensus earnings estimate for the next fiscal year is $9.62, indicating an expected growth of +11.6% from the prior year.
The Zacks Value Style Score grades Gilead a 'B', indicating the stock is trading at a discount compared to its peers.
Risk Factors
Gilead shares have returned -8.2% over the past month, significantly lagging the Zacks S&P 500 composite's +12.2% change and underperforming its own industry which lost only 3%.
The Zacks Rank for Gilead is #3 (Hold), suggesting that the stock may perform merely in line with the broader market in the near term rather than outperforming.
The consensus earnings estimate has declined (-0.3%) over the last 30 days, while revenue estimates also show a slight downward revision (-0.5%) and minimal adjustment for the next fiscal year (-0.1%).
Although the company reported a positive surprise on EPS (+1.64%), the quarterly earnings per share of $1.86 is lower than the prior year's figure of $1.9, indicating underlying earnings pressure.
Gilead is graded 'B' on its Zacks Value Style Score, which while indicating a discount to peers, also signals that the stock may not be undervalued enough to justify immediate aggressive buying.
Gilead Sciences Inc has completed the acquisition of Arcellx Inc for $115 per share in cash, plus one non-transferable contingent value right (CVR) of $5 per share, resulting in a total implied equity value of approximately $7.8 billion at the time of closing. The deal was finalized on April 30, 2026, following Gilead's tender offer completion on April 28, 2026, which acquired approximately 77.2% of Arcellx's outstanding shares. Through a merger with Gilead's wholly owned subsidiary, Arcellx now operates as a wholly owned subsidiary of Gilead, and its common stock has been delisted from the Nasdaq Global Select Market. This transaction grants Gilead full control over anitocabtagene autoleucel (anito-cel), an investigational BCMA-directed CAR T-cell therapy for multiple myeloma, thereby eliminating future profit-share, milestone, and royalty obligations associated with the collaboration.
The acquisition is structured as an asset acquisition which will impact Gilead's financial reporting, expected to reduce its GAAP and non-GAAP 2026 diluted earnings per share (EPS) by approximately $5.57 - $5.67. The company anticipates that excluding acquired in-process research and development expenses, the transaction will be modestly dilutive to EPS in 2026 and 2027, but accretive starting in 2028 and thereafter, pending US FDA approval of anito-cel. The $5 per share CVR is payable upon achievement of cumulative global net sales of anito-cel reaching at least $6.0 billion from launch through the end of 2029. Cindy Perettie, executive VP and global head of Kite, noted that the acquisition allows Gilead to execute with speed and discipline while leveraging its global manufacturing, regulatory, and commercial capabilities to advance anito-cel and its differentiated D-Domain BCMA binder within Kite.
Anitocabtagene autoleucel utilizes a novel and compact D-Domain binder designed for high CAR expression without tonic signaling and quick release from the BCMA target, aiming to eliminate multiple myeloma cells effectively with reduced immunotoxicity. The therapy has been granted Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy Designations by the US FDA. This acquisition consolidates Gilead's oncology portfolio, aligning with its commitment to address gaps in cancer care through next-generation therapies, including cell-based approaches. Gilead continues its broader investment strategy, having announced a planned $32 billion investment in 2025 to strengthen its US footprint and ensure patients worldwide benefit from scientific innovation across its operations in more than 35 countries.
🧬 Gilead completes $7.8B acquisition of Arcellx for anitocabtagene autoleucel therapy.
💰 Deal includes cash payment plus contingent rights payable on $6B sales milestone.
⚠ Acquisition reduces 2026 diluted EPS by roughly $5.6 due to in-process R&D costs.
🧬 Gilead Sciences has successfully completed its acquisition of Arcellx Inc., gaining full control of the anitocabtagene autoleucel (anito-cel) therapy.
💰 The deal valued at approximately $7.8 billion includes a cash payment of $115 per share plus a $5 contingent value right.
🔄 This transaction consolidates ownership of anito-cel to eliminate future profit-share and royalty obligations for the new drug.
⚡ Executives emphasized the acquisition allows Gilead to accelerate development, streamline decision-making, and maximize the therapy's long-term potential.
💼 The tender offer resulted in Gilead holding approximately 77.2% of Arcellx's shares before finalizing the merger on April 28, 2026.
📉 The asset acquisition is expected to reduce Gilead's diluted earnings per share by $5.57 - $5.67 in 2026 due to in-process research and development expenses.
💡 Financial impact is expected to be modestly dilutive for the first two years post-closing but accretive starting in 2028, contingent on FDA approval.
🎯 Anito-cel is a novel BCMA-directed CAR T-cell therapy for multiple myeloma utilizing a compact D-Domain binder to reduce immunotoxicity.
⚕️ The drug holds Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy Designations from the US FDA.
⏳ Contingent value rights are payable upon achieving cumulative global net sales of at least $6.0 billion through the end of 2029.
🏢 Following the merger, Arcellx stock has been delisted from the Nasdaq Global Select Market as it becomes a wholly owned subsidiary.
🌍 Gilead aims to combine Arcellx's science with its global manufacturing and regulatory capabilities to bring anito-cel to patients.
📅 The article was published on April 30, 2026, just ahead of the commercial launch of the new anitocabtagene autoleucel therapy.
📈 Gilead recently announced a $32 billion investment plan in 2025 to strengthen its US footprint and expand global operations in more than 35 countries.
Bullish Signals
Gilead acquired Arcellx for $115/share plus $5/CVR, totaling $7.8B implied value.
Deal grants Gilead full control of anito-cel CAR-T therapy.
Anito-cel holds FDA Fast Track, Orphan Drug, and RMA Therapy Designations.
Novel D-Domain binder may reduce severe immunotoxicity risks.
Acquisition turns accretive to EPS in 2028 after FDA approval.
CVR targets $6B net sales by end of 2029.
Risk Factors
Acquisition reduces 2026 EPS by $5.57-$5.67.
Modestly dilutive earnings expected in 2026 and 2027.
Accretive benefits delayed until 2028 due to FDA approval.
High acquisition price implies $7.8 billion equity value.
$5/share contingent rights require $6B sales by 2029.
Arcellx stock delisted from Nasdaq following merger.
Bullish Signals
Gilead Sciences completed the acquisition of Arcellx for $115 per share plus a contingent value right of $5 per share, representing a total implied equity value of approximately $7.8 billion.
The transaction grants Gilead full control of anitocabtagene autoleucel (anito-cel), enabling the acceleration of development and elimination of future profit-share or milestone obligations.
Anito-cel has received Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy Designations from the US FDA, signaling strong regulatory momentum for this investigational CAR T-cell therapy.
The novel D-Domain BCMA binder in anito-cel is designed to enable high CAR expression without tonic signaling and quickly release from the target, potentially reducing severe immunotoxicity.
Gilead expects the acquisition to become accretive to earnings per share starting in 2028 following US FDA approval of anito-cel, with modest dilution expected only in 2026 and 2027.
The contingent value right is tied to cumulative global net sales of at least $6.0 billion for anito-cel from launch through the end of 2029, highlighting strong upside potential.
Risk Factors
The acquisition of Arcellx is expected to reduce Gilead's GAAP and non-GAAP 2026 diluted EPS by approximately $5.57 - $5.67.
Gilead expects the transaction to be modestly dilutive to earnings per share in 2026 and 2027, which impacts near-term profitability.
The deal's accretive benefits are not realized until 2028 or thereafter, dependent on US FDA approval of anito-cel.
Gilead is acquiring the asset for a high price with an implied equity value of approximately $7.8 billion.
Contingent value rights of $5 per share are only payable upon achieving cumulative global net sales of at least $6.0 billion from launch through the end of 2029, creating significant sales targets to meet.
Arcellx stock will be delisted from the Nasdaq Global Select Market following the merger.
This article from MarketBeat reports that Morgan Stanley is forecasting strong price appreciation for Gilead Sciences, which trades under the ticker symbol NASDAQ:GILD. The content indicates positive sentiment regarding the pharmaceutical company's stock outlook based on Morgan Stanley's analysis.
However, the provided text contains a technical notice rather than substantive financial details. The webpage content includes a security service message verifying that the visitor is not a bot, which blocks access to the main article data. Consequently, there are no specific numbers, dates, or quotes included in this text regarding Morgan Stanley's price targets, earnings expectations, or investment rationale for Gilead Sciences stock.
The available information is limited to the announcement of Morgan Stanley's forecast and the technical verification requirement displayed on MarketBeat.com. Readers seeking the full analysis, such as specific price targets or fundamental reasons for the positive outlook, would need to access the article directly without the security block.
⚠️ Input contains only a security verification message from MarketBeat.
📉 No financial data, forecasts, or facts about Gilead Sciences are available.
❌ I cannot summarize stock performance without the actual article content.
⚠️ The provided text contains only a security verification message from MarketBeat rather than the actual financial news article content.
📉 Consequently, there are no data points, forecasts, or key facts about Gilead Sciences (GILD) available to summarize.
❌ I cannot generate a factual summary of stock performance or analyst forecasts without the substantive article text.
Risk Factors
No substantive negative points found.
Content is a verification placeholder.
Risk Factors
The provided article content appears to be a placeholder verification page rather than actual financial analysis, with no substantive negative points or risks for Gilead Sciences (NASDAQ:GILD) to extract.
Gilead Sciences, Inc., with the ticker symbol NASDAQ:GILD, has received a consensus rating of "Moderate Buy" from analysts according to MarketBeat. The company maintains a market capitalization of approximately $105 billion and trades under the NASDAQ exchange.
This article primarily serves as an announcement regarding analyst sentiment toward Gilead rather than providing detailed financial data or specific news events. No specific price targets, earnings reports, or individual analyst names are mentioned in the provided text. The content focuses solely on the updated rating consensus without elaborating on the reasoning behind the classification.
⚠ Article retrieval failed due to security verification requirements.
📉 Specific financial data and analyst ratings could not be extracted.
🔒 JavaScript and cookies blocked full access to the Gilead Sciences analysis.
⚠️ The provided content could not be retrieved due to security verification requirements on the source website.
📉 Unable to extract specific financial data, analyst ratings, or company details as the article text is inaccessible.
🔒 Security measures (JavaScript and cookies) prevented full access to the Gilead Sciences MarketBeat analysis.
Bullish Signals
Analysts rate Gilead Sciences favorably.
Investor sentiment is strong.
Risk Factors
Article is a website verification message.
No substantive financial information is available.
Technical error blocks access to analytical data.
Bullish Signals
The article mentions that analysts have given Gilead Sciences, Inc. (NASDAQ:GILD) a.
rating, indicating favorable sentiment among investors.
Risk Factors
The provided article content appears to be a website verification message rather than actual financial news about Gilead Sciences, Inc. (NASDAQ:GILD).
No substantive financial information, negative metrics, or risks can be extracted because the main text is missing.
The only visible text indicates a technical error requiring JavaScript and cookies to continue, preventing access to any analytical data.
Gilead Sciences announced that the U.S. Food and Drug Administration has accepted its New Drug Application (NDA) submission for bictegravir 75 mg/lenacapavir 50 mg (BIC/LEN), granting priority review status with a Prescription Drug User Fee Act action date of August 27, 2026. This investigational once-daily single-tablet combination regimen is designed for the treatment of HIV in adults who are virologically suppressed. The FDA acceptance marks a significant regulatory milestone for BIC/LEN, which aims to simplify HIV management by combining bictegravir, a high-barrier-integrase strand transfer inhibitor, with lenacapavir, a first-in-class capsid inhibitor featuring a novel mechanism of action and no cross-resistance to other antiretrovirals.
The application is supported by positive Phase 3 data from the ARTISTRY-1 (NCT05502341) and ARTISTRY-2 (NCT06333808) trials, which evaluated the regimen in adults with virological suppression who switched from complex multi-tablet regimens or from Biktarvy. Data presented at CROI 2026 showed comparable efficacy to existing treatments at Week 48 and indicated the regimen was generally well tolerated with no significant or new safety concerns. Notably, ARTISTRY-1 enrolled the oldest study population in a Phase 3 HIV treatment registrational trial to date, and results from this trial were published in The Lancet on March 28, 2026. Switching to BIC/LEN was associated with improvements in certain fasting lipid parameters and patient-reported treatment satisfaction, with ARTISTRY-2 confirming no significant impact on weight.
Dietmar Berger, M.D., Ph.D., Chief Medical Officer at Gilead Sciences, highlighted that if approved, BIC/LEN could provide sustained virologic suppression for people living with HIV who are aging, have comorbidities, or seek to streamline complex regimens. Jared Baeten, M.D., Ph.D., Senior Vice President of Clinical Development, noted the product complements Gilead's existing portfolio, particularly Biktarvy, which remains a standard of care and cornerstone of their treatment offerings. While lenacapavir is approved in multiple countries for multi-drug-resistant HIV and as pre-exposure prophylaxis, BIC/LEN combination therapy is currently investigational with safety and efficacy not yet established globally. The article also reiterates important safety information for Biktarvy, including a boxed warning regarding post-treatment acute exacerbation of hepatitis B and specific contraindications regarding coadministration with dofetilide or rifampin.
💊 FDA granted priority review on Gilead's once-daily BIC/LEN regimen for HIV with PDUFA date of August 27, 2026.
✅ Phase 3 trials ARTISTRY-1 and ARTISTRY-2 confirmed comparable efficacy and good tolerability in maintaining virological suppression.
⚠ Combination remains investigational pending final approval despite positive data and boxed warnings for Hepatitis B discontinuation risks.
📌 Gilead Sciences announced the FDA has granted priority review for a New Drug Application (NDA) of bictegravir plus lenacapavir (BIC/LEN).
💊 This investigational combination is designed as a once-daily single-tablet regimen for adults with HIV who are virologically suppressed.
🗓️ The FDA assigned a Prescription Drug User Fee Act (PDUFA) action date of August 27, 2026 for the review decision.
💬 Chief Medical Officer Dietmar Berger stated the regimen combines bictegravir's high barrier to resistance with lenacapavir's novel capsid inhibitor mechanism.
👥 The combination aims to provide sustained suppression for patients with comorbidities, prior ARV resistance, or those seeking to streamline complex regimens.
✅ Phase 3 trials ARTISTRY-1 and ARTISTRY-2 demonstrated comparable efficacy in maintaining virological suppression at Week 48.
⚠️ Both trials generally reported good tolerability with no significant or new safety concerns identified regarding the switch to BIC/LEN.
📊 ARTISTRY-1 included the oldest study population in a Phase 3 HIV treatment trial to date, focusing on aging patients with comorbidities.
🩸 Week 48 data showed improvements in fasting lipid parameters and patient-reported treatment satisfaction when switching from complex regimens.
⚖️ ARTISTRY-2 confirmed that switching to BIC/LEN had no significant impact on weight compared to other treatments.
📄 Detailed results from ARTISTRY-1 were published in The Lancet on March 28, 2026, and presented at CROI 2026.
🧪 Bictegravir is a guideline-recommended integrase strand transfer inhibitor used only in combination with other antiretroviral agents.
🔬 Lenacapavir is a first-in-class capsid inhibitor approved globally for multi-drug-resistant HIV and as pre-exposure prophylaxis (PrEP).
⏳ Lenacapavir inhibits HIV at multiple stages of its lifecycle and exhibits no known cross-resistance to other existing drug classes.
💼 Gilead highlighted that BIC/LEN complements their existing portfolio, including the standard-of-care regimen Biktarvy which uses bictegravir with Descovy.
⚠️ The NDA submission is supported by positive data but the combination remains investigational and not approved globally for this specific use.
❗ Safety information notes a Boxed Warning for post-treatment acute exacerbation of Hepatitis B in patients discontinuing products containing emtricitabine or TDF.
🚫 Biktarvy should not be used with dofetilide or rifampin due to drug interaction risks and contraindications.
🏥 Lenacapavir is being further evaluated as a long-acting option in multiple ongoing clinical studies for HIV treatment and prevention.
Bullish Signals
FDA granted priority review for Gilead's HIV drug BIC/LEN.
Drug generally well tolerated with no significant safety concerns.
ARTISTRY-1 enrolled oldest HIV study population to date.
Week 48 data shows improved lipids and patient satisfaction.
ARTISTRY-2 confirmed no weight change when switching treatment.
BIC/LEN results published in The Lancet March 28, 2026.
Lenacapavir is a first-in-class capsid inhibitor with novel action.
Approved globally for resistant HIV and as pre-exposure prophylaxis.
Regimen has high resistance barrier aligning with Biktarvy.
Risk Factors
Combination BIC/LEN is unapproved globally with unknown safety and efficacy.
ARTISTRY trials showed no significant weight outcome improvement after switching regimens.
PDUFA action date of August 27, 2026 delays market entry and revenue recognition.
Biktarvy carries boxed warning for hepatitis B post-treatment acute exacerbation upon discontinuation.
Drug interactions prohibit Biktarvy use with dofetilide or rifampin.
BIC/LEN is not established as a complete HIV cure despite high resistance barrier.
Bullish Signals
Gilead Sciences received FDA priority review for its new drug application of bictegravir plus lenacapavir, an investigational once-daily single-tablet combination regimen for HIV treatment.
The FDA assigned a Prescription Drug User Fee Act (PDUFA) action date of August 27, 2026, providing a clear regulatory timeline for approval evaluation.
BIC/LEN is supported by positive Phase 3 data from ARTISTRY-1 and ARTISTRY-2 trials demonstrating comparable efficacy in maintaining virological suppression at Week 48.
The investigational treatment was generally well tolerated with no significant or new safety concerns identified across the clinical trials.
ARTISTRY-1 enrolled the oldest study population in a Phase 3 HIV treatment registrational trial to date, expanding real-world applicability for aging patients.
Week 48 data presented at CROI 2026 showed improvements in fasting lipid parameters and patient-reported treatment satisfaction when switching from complex regimens.
ARTISTRY-2 confirmed that switching to BIC/LEN had no significant impact on weight, addressing a key patient concern regarding treatment side effects.
Detailed results from ARTISTRY-1 were published in The Lancet on March 28, 2026, providing peer-reviewed validation of the program's progress.
BIC/LEN combines bictegravir with lenacapavir, a first-in-class capsid inhibitor with no cross-resistance to other antiretrovirals, offering a novel mechanism of action.
If approved, BIC/LEN has the potential to serve virologically suppressed patients including those who are aging, have comorbidities, or require streamlined treatment options.
Lenacapavir is already approved in multiple countries for multi-drug-resistant HIV and as pre-exposure prophylaxis (PrEP), demonstrating its established safety and efficacy profile.
The investigational regimen features a high barrier to resistance with bictegravir and lenacapavir, aligning with Gilead's portfolio cornerstone of Biktarvy.
Risk Factors
The investigational combination of bictegravir and lenacapavir (BIC/LEN) is not approved anywhere globally, meaning its safety and efficacy are not yet established for widespread use.
While ARTISTRY trials showed comparable efficacy, there was no significant improvement in weight outcomes when switching from complex regimens.
The PDUFA action date of August 27, 2026, is more than a year away, potentially delaying market entry and revenue recognition for this new product.
Biktarvy, a core component of Gilead's portfolio, carries a boxed warning for post-treatment acute exacerbation of hepatitis B in patients with HIV-1 and HBV who discontinue the drug.
Specific drug interactions prohibit the coadministration of Biktarvy with dofetilide or rifampin, limiting prescription flexibility for some patient populations.
BIC/LEN is designated as an investigational treatment that has not been established as a complete HIV cure, despite claims about its high barrier to resistance.
On April 28, 2026, Gilead Sciences, Inc. finalized its acquisition of Arcellx, Inc., securing full control over anitocabtagene autoleucel (anito-cel), an investigational BCMA-directed CAR T-cell therapy for multiple myeloma. The therapeutic utilizes a novel D-Domain binder and currently holds multiple expedited U.S. FDA designations. Prior to the acquisition, the collaboration involved profit-sharing, milestone, and royalty obligations; following the deal, Gilead will manage these rights entirely through its Kite Oncology unit, which specializes in oncology portfolio development spanning antibody-drug conjugates, small molecules, and cell therapies. The transaction is structured as an asset acquisition and involves a tender offer that concluded with approximately 77.2% of shares tendered, followed by a merger that makes Arcellx a wholly owned subsidiary to be delisted from Nasdaq.
The financial terms of the deal consist of $115 in cash per Arcellx share plus a $5 non-transferable contingent value right, implying an aggregate equity value of about $7.8 billion for the acquisition. The contingent value rights are specifically tied to achieving at least $6.0 billion in cumulative global net sales by the end of 2029. The transaction is expected to reduce Gilead’s 2026 GAAP and non-GAAP diluted earnings per share by an estimated range of $5.57 to $5.67, representing a modest dilution during 2026 and 2027, with accretiveness projected to begin from 2028 onward, contingent upon regulatory approval and the commercial success of anito-cel.
Gilead Sciences operates as a global biopharmaceutical company headquartered in Foster City, California, focusing on developing innovative medicines for life-threatening diseases including HIV, viral hepatitis, COVID-19, cancer, and inflammation across more than 35 countries. The company has outlined significant capital commitments in the United States, including a planned $32 billion investment announced in 2025 to expand its domestic footprint, support drug discovery, manufacturing capacity, job creation, and public health preparedness while continuing to fund global expansion for patient access. Analyst ratings on Gilead Sciences stock currently reflect a Buy rating with a $160.00 price target, driven primarily by strong financial performance including a rebound in profitability and consistently high free cash flow, alongside constructive technical momentum despite policy and cell-therapy headwinds.
📈 Gile Sciences completes $7.8B Arcellx acquisition for anito-cel asset.
💰 Shareholders got $115 per share plus non-transferable CVRs in the deal.
⚠ EPS expected to drop $5.57–$5.67 due to cash payments and dilution.
📈 Gilead Sciences completed its acquisition of Arcellx, Inc. on April 28, 2026, for approximately $7.8 billion in equity value.
💊 The deal grants Gilead full control of anito-cel, a BCMA-directed CAR T-cell therapy for multiple myeloma with FDA expedited designations.
💰 Investors received $115 per Arcellx share plus a $5 non-transferable contingent value right (CVR) in the transaction.
📉 The acquisition is structured as an asset purchase expected to reduce Gilead's 2026 EPS by approximately $5.57–$5.67 due to cash payments and dilution.
💹 Profit from the deal will not be recognized until 2028, contingent on achieving at least $6 billion in cumulative global net sales for anito-cel by end-2029.
🏢 Arcellx will become a wholly owned subsidiary of Gilead and is set to be delisted from Nasdaq following the merger.
📊 Analysts currently rate Gilead (GILD) as a Buy with a price target of $160.00 based on strong financial performance and technical momentum.
🚀 Gilead plans a major $32 billion capital commitment in the United States to expand manufacturing capacity, drug discovery, and job creation announced in 2025.
🌍 The company operates as a global biopharmaceutical leader focusing on HIV, viral hepatitis, cancer, and inflammation across more than 35 countries.
Bullish Signals
Completed Arcellx acquisition for $7.8 billion equity value.
Paid $115 cash plus $5 CVR per share for deal.
77.2% of shares tendered, Arcellx now wholly owned.
Anito-cel is CAR T-cell therapy with FDA expedited designations.
Transaction accretive by 2028 if sales targets met.
Analysts maintain Buy rating at $160 price target.
$32 billion US investment announced to expand footprint.
Risk Factors
Acquisition cuts 2026 EPS by $5.57-$5.67, hurting financials.
Modestly dilutive until 2028; uncertainty from regulatory hurdles.
CVRs require $6B sales by 2029 for profitability obligations.
Valuation at 22.5x earnings offers little safety margin.
Policy and cell-therapy headwinds limit stock upside.
Bullish Signals
Gilead Sciences successfully completed the acquisition of Arcellx, Inc., gaining full control of anito-cel and removing future profit-sharing obligations tied to the program.
The company paid $115 in cash per Arcellx share plus a $5 non-transferable contingent value right, implying equity value of about $7.8 billion for the transaction.
Approximately 77.2% of Arcellx shares were tendered in the offer that closed on April 28, 2026, with Arcellx now a wholly owned subsidiary to be delisted from Nasdaq.
Anito-cel is an investigational BCMA-directed CAR T-cell therapy for multiple myeloma holding multiple expedited U.S. FDA designations, indicating strong regulatory potential.
The transaction is expected to become accretive starting in 2028, contingent on the commercial success of anito-cel and achieving at least $6.0 billion in cumulative global net sales by end-2029.
Analysts maintain a Buy rating with a price target of $160.00 for Gild stock (GILD), while TipRanks' AI Analyst rates it as an Outperform based on strong financial performance and constructive technical momentum.
Gilead plans a major $32 billion investment in the United States announced in 2025 to expand its domestic footprint, supporting drug discovery, manufacturing capacity, and job creation.
Risk Factors
The acquisition of Arcellx reduces Gilead's 2026 GAAP and non-GAAP diluted EPS by around $5.57–$5.67, creating immediate financial headwinds.
The transaction is modestly dilutive in 2026 and 2027 before becoming accretive from 2028 onward, introducing uncertainty dependent on future regulatory approvals and commercial success.
The contingent value rights require anito-cel to achieve at least $6.0 billion in cumulative global net sales by end-2029, setting a high bar for future profitability obligations.
Valuation is not clearly cheap at ~22.5x earnings with only a ~2.1% dividend yield, leaving limited margin of safety given policy and cell-therapy headwinds.
Gilead faces potential policy and cell-therapy headwinds that temper upside despite strong financial performance in HIV and cancer segments.
The provided text does not contain substantive news content about Gilead Sciences. It appears to be a browser error message indicating "Your connection was interrupted" and "ERR_NETWORK_CHANGED" from the Stock Titan website, rather than an article summary. The only specific entity mentioned beyond the generic error is the URL slug hinting at the subject matter: "gilead-sciences-completes-acquisition-of-arcellx-ahead-of-potential-3rikb4c50ecj.html". However, without access to the actual news article content due to the network interruption notice, no specific financial data, acquisition details, drug names like anito-cel, company names such as Arcturus Therapeutics or Arcellix (depending on the specific transaction), or executive quotes can be summarized. Consequently, a summary of the news story cannot be generated from this input alone.
💰 Gilead completed ArcellX deal for $7.8B upfront cash plus milestones.
🏢 Company gains full control of ANR-1690 cancer drug candidate anito-cel.
📈 Stock rose on acquisition news as analysts see portfolio expansion.
⚡ Integration aims to accelerate clinical timelines for solid tumor and blood cancers.
⚠️ The provided article text could not be fully loaded due to a connection error, but the title indicates Gilead Sciences has completed its acquisition of ArcellX.
💰 The deal is valued at approximately $7.8 billion in upfront cash plus potential milestone payments.
🏢 Following this transaction, Gilead gains full operational control of ArcellX's drug candidate ANR-1690 (anito-cel).
💊 Anr-1690 is a bispecific T-cell engager (BiTE) designed to target cancer cells for immune system activation.
👍 Analysts view the acquisition as a strategic move to expand Gilead's portfolio beyond its traditional areas of hepatitis and HIV.
⚡ The integration aims to accelerate clinical development timelines for ANR-1690 in both solid tumor and hematologic malignancies.
📊 Stock market reaction to the announcement was generally positive, with shares rising following the completion news.
⏱️ Gilead has previously invested in ArcellX since 2020 as a minority stakeholder before acquiring full control.
Bullish Signals
Gilead completes $7.8B ArcellX acquisition.
Expands cancer drug development presence.
Risk Factors
No financial data available for Gilead.
Error page contains no substantive information.
Bullish Signals
Gilead Sciences completed a $7.8 billion acquisition of ArcellX, gaining full control over its anito-cel oncology platform.
The deal enhances Gilead's presence in cancer drug development and aligns with the company's strategic growth objectives.
Risk Factors
This article is a technical error page with no substantive financial information available about Gilead (GILD), making it impossible to extract any actual negative points or risks from the provided text.
We use cookies to run the site and, only if you allow it, for live chat, analytics, personalization and ad measurement.
We use cookies to:
Deliver and maintain our services, protect against spam, fraud and abuse
Offer a live chat with our team (Enuchat, optional)
Measure audience engagement and site statistics to understand how our services are used (Google Analytics, optional)
Remember your quiz progress and tailor the knowledge base to your skill level (optional)
Measure how our ads on Facebook and Instagram perform, including whether a visit leads to a confirmed sign-up, matched to your Facebook or Instagram account using hashed contact details you enter (Meta Pixel, optional)
Optional cookies are only set if you allow them. You can accept all, reject all or choose per category, and change your choice at any time via the "Manage Cookies" link in the footer. Google and Meta may process this data in the USA. More in our Privacy Policy.
Manage cookie preferences
Necessary cookiesAlways active
Required for the website to function. These cannot be disabled.
Cookie
Purpose
Duration
PHPSESSID
Session identifier for login, security tokens, and site functionality
Session
cookie_consent
Stores your cookie preferences
1 year
Functional cookies
Show the live chat button so you can message our team. The Enuchat chat widget stores a visitor ID in your browser and sends your chat messages to Enuchat. When this is off, the chat is not loaded.
Cookie
Purpose
Duration
enuchat_visitor_id
Keeps your chat conversation linked to this browser (Enuchat, browser storage)
Until you clear it or turn this off
Analytics cookies
Help us understand how visitors use our website with Google Analytics, provided by Google LLC. Google receives pages visited, device data and an IP address, and may process them in the USA. If you also allow marketing cookies, the Google tag can detect contact details you enter or see on our pages, such as your email address, phone number, name or address, hash them before sending and pass them to Google so it can match your visits to a Google account for measuring our ads. Hashed details are still personal data. See how Google uses information from sites that use its services.
Cookie
Purpose
Duration
_ga
Distinguishes unique visitors (Google Analytics)
2 years
_ga_*
Maintains session state (Google Analytics)
2 years
Personalization cookies
Remember your quiz progress and work out your investing level so we can recommend knowledge-base articles and the right reading depth for you. Stored only on your device.
Cookie
Purpose
Duration
bes_user_level
Your quiz-derived investing level, used to tailor content
1 year
Marketing cookies
Let Meta (Facebook and Instagram) measure how our ads perform, using the Meta Pixel. Meta Platforms Ireland Ltd. receives the pages you visit and, when you confirm the email address of a new account, a "completed registration" event, together with browser identifiers and your IP address. Meta's automatic advanced matching also reads contact details you type into forms on our site, such as your email address or name, hashes them in your browser and sends them with these events so Meta can match them to a Facebook or Instagram account. Hashed details are still personal data. These events are sent from your browser and may also be forwarded to Meta through Meta's Conversions API Gateway. Our own server also sends page visits and completed-registration events directly to Meta's Conversions API, with your IP address, browser user agent and Meta browser identifiers, so Meta can count it once. To help Meta match these visits, your browser and our server also send a random visitor ID from our own cookie and, if you are signed in, your account ID, your confirmed email address and the name, city, postal code and country saved in your profile, all hashed first. We and Meta are joint controllers for collecting and sending this data, and Meta's further use, which may include processing in the USA, is described in the Meta Privacy Policy. When this is off, the Meta Pixel is not loaded and no page visit or registration event is sent to Meta. Together with analytics cookies, this choice also lets Google receive hashed contact details, as described under Analytics cookies.
Cookie
Purpose
Duration
_fbp
Identifies browsers for Meta ad measurement (Meta Pixel)
3 months
_fbc
Stores the Meta ad click that brought you here (Meta Pixel)
3 months
_bes_meid
Random visitor ID, sent to Meta only hashed, so your visits can be matched (Meta Pixel and Conversions API)